Bassel El-Rayes MD

Winship Cancer Institute
Center Member, Winship

(404) 778-1900
bassel.el-rayes@emoryhealthcare.org

Academic Appointment

Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine

Education

Degrees

MD from American University of Beirut
BS from American University of Beirut

Research

Focus

My research is on translational projects related to gastrointestinal malignancies, specifically pancreatic and colorectal cancer, to bring observations derived from in vitro models of cancer cell growth to the clinic. I closely collaborate with basic scientists in studies that target the HSP90, NF-kB cell signaling pathways such as HDAC-6 in pancreatic cancer cells.

Publications

Paricalcitol plus hydroxychloroquine enhances gemcitabine activity and induces mesenchymal to epithelial transition in pancreatic ductal adenocarcinoma: A single cell RNA-seq analysis.
Cancer Lett Volume: 625 Page(s): 217809
08/10/2025 Authors: Nagaraju GP; Saddala MS; Sarvesh S; Bandi DSR; Khaliq AM; Masood A; Akce M; El-Rayes BF
A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer.
Cancer Res Volume: 85 Page(s): 956 - 972
03/03/2025 Authors: Foote JB; Mattox TE; Keeton AB; Chen X; Smith FT; Berry K; Holmes TW; Wang J; Huang C-H; Ward A
Molecular Characterization and Clinical Outcomes of Pancreatic Neuroendocrine Neoplasms Harboring PAK4-NAMPT Alterations.
JCO Oncol Adv Volume: 2 Page(s): e2400032
01/01/2025 Authors: Azar I; Khan HY; Bannoura SF; Gandhi N; Uddin MH; Nagasaka M; Gong J; Nazha B; Choucair K; Vojjala N
RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth.
Cancer Lett Volume: 604 Page(s): 217275
11/01/2024 Authors: Bannoura SF; Aboukameel A; Khan HY; Uddin MH; Jang H; Beal EW; Thangasamy A; Shi Y; Kim S; Wagner K-U
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040.
Ann Oncol Volume: 35 Page(s): 537 - 548
06/01/2024 Authors: Melero I; Yau T; Kang Y-K; Kim T-Y; Santoro A; Sangro B; Kudo M; Hou M-M; Matilla A; Tovoli F
Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers.
Mol Cancer Ther Volume: 22 Page(s): 1422 - 1433
12/01/2023 Authors: Khan HY; Nagasaka M; Aboukameel A; Alkhalili O; Uddin MH; Bannoura SF; Mzannar Y; Azar I; Beal EW; Tobon ME
DNA-PK is activated by SIRT2 deacetylation to promote DNA double-strand break repair by non-homologous end joining.
Nucleic Acids Res Volume: 51 Page(s): 7972 - 7987
08/25/2023 Authors: Head PE; Kapoor-Vazirani P; Nagaraju GP; Zhang H; Rath SK; Luong NC; Haji-Seyed-Javadi R; Sesay F; Wang S-Y; Duong DM
Time to treatment initiation and its impact on real-world survival in metastatic colorectal cancer and pancreatic cancer.
Cancer Med Volume: 12 Page(s): 3488 - 3498
02/01/2023 Authors: Gbolahan O; Hashemi-Sadraei N; Yash S; Williams G; Ramachandran R; Kim Y-I; Paluri R; Outlaw D; El-Rayes B; Nabell L
Epigenetics in hepatocellular carcinoma.
Semin Cancer Biol Volume: 86 Page(s): 622 - 632
11/01/2022 Authors: Nagaraju GP; Dariya B; Kasa P; Peela S; El-Rayes BF
Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma.
Nat Commun Volume: 13 Page(s): 6418
10/27/2022 Authors: Ravindranathan S; Passang T; Li J-M; Wang S; Dhamsania R; Ware MB; Zaidi MY; Zhu J; Cardenas M; Liu Y
Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer.
Clin Cancer Res Volume: 28 Page(s): 4336 - 4345
10/03/2022 Authors: Ruggieri AN; Yarchoan M; Goyal S; Liu Y; Sharon E; Chen HX; Olson BM; Paulos CM; El-Rayes BF; Maithel SK
Role of local therapy in the management of patients with metastatic anal squamous cell carcinoma: a National Cancer Database study.
J Gastrointest Oncol Volume: 13 Page(s): 2306 - 2321
10/01/2022 Authors: Atallah RP; Zhang Y; Zakka K; Jiang R; Huang Z; Shaib WL; Diab M; Akce M; Wu C; El-Rayes BF
Epidemiology of early esophageal adenocarcinoma.
Clin Endosc Volume: 55 Page(s): 372 - 380
05/01/2022 Authors: Hang T-VP; Spiritos Z; Gamboa AM; Chen Z; Force S; Patel V; Chawla S; Keilin S; Saba NF; El-Rayes B
Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers.
Cancers (Basel) Volume: 14
03/29/2022 Authors: Kang S; El-Rayes BF; Akce M
Correlates of financial toxicity in adult cancer patients and their informal caregivers.
Support Care Cancer Volume: 30 Page(s): 217 - 225
01/01/2022 Authors: Sadigh G; Switchenko J; Weaver KE; Elchoufi D; Meisel J; Bilen MA; Lawson D; Cella D; El-Rayes B; Carlos R
Successful Liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report.
Oncol Res Treat Volume: 45 Page(s): 430 - 437
01/01/2022 Authors: Kang S; Magliocca J; Sellers M; Roccaro G; Zheng W; Pectasides M; Draper A; Guadagno J; El-Rayes B; Akce M
Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors.
Oncology Volume: 100 Page(s): 131 - 139
01/01/2022 Authors: Allaw MB; Switchenko JM; Khalil L; Wu C; Alese OB; Akce M; Draper A; Jones AT; El-Rayes B; Shaib W
A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186.
Cancer Immunol Immunother Volume: 70 Page(s): 3337 - 3348
11/01/2021 Authors: Herting CJ; Farren MR; Tong Y; Liu Z; O'Neil B; Bekaii-Saab T; Noonan A; McQuinn C; Mace TA; Shaib W
Negative enrichment of circulating tumor cells from unmanipulated whole blood with a 3D printed device.
Sci Rep Volume: 11 Page(s): 20583
10/18/2021 Authors: Chu C-H; Liu R; Ozkaya-Ahmadov T; Swain BE; Boya M; El-Rayes B; Akce M; Bilen MA; Kucuk O; Sarioglu AF
PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus.
Mol Cancer Ther Volume: 20 Page(s): 1836 - 1845
10/01/2021 Authors: Mpilla GB; Uddin MH; Al-Hallak MN; Aboukameel A; Li Y; Kim SH; Beydoun R; Dyson G; Baloglu E; Senapedis WT
Targeting KRAS in pancreatic cancer: new drugs on the horizon.
Cancer Metastasis Rev Volume: 40 Page(s): 819 - 835
09/01/2021 Authors: Bannoura SF; Uddin MH; Nagasaka M; Fazili F; Al-Hallak MN; Philip PA; El-Rayes B; Azmi AS
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
J Hepatol Volume: 75 Page(s): 600 - 609
09/01/2021 Authors: Kudo M; Matilla A; Santoro A; Melero I; Gracin AC; Acosta-Rivera M; Choo S-P; El-Khoueiry AB; Kuromatsu R; El-Rayes B
Crosstalk Between Cancer Associated Fibroblast Soluble Mediators and Pancreatic Cancer Cells Facilitate an Invasive Phenotype
Volume: 50 Page(s): 1061 - 1061
08/01/2021 Authors: Greene E; Ware M; Herting C; Maithel S; Sarmiento J; El-Rayes BF; Tucker-Burden C; Marcus A; Lesinski GB
PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus
Volume: 50 Page(s): 1105 - 1105
08/01/2021 Authors: Uddin M; Mpilla G; Al-Hallak MN; Aboukameel A; Li Y; Kim S; Beydoun R; Dyson G; Baloglu E; Senapedis W
Vasoactive Intestinal Peptide Receptor Signaling: A Novel and Targetable Immune Checkpoint Pathway in Pancreatic Cancer
Volume: 50 Page(s): 1091 - 1092
08/01/2021 Authors: Ravindranathan S; Tenzin P; Ware M; Zaidi M; Wang S; Dhamsania R; Zhu J; Liu Y; Liu Y; Gumber S
Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer.
Oncologist Volume: 26 Page(s): 668 - 675
08/01/2021 Authors: Sahin IH; Goyal S; Pumpalova Y; Sonbol MB; Das S; Haraldsdottir S; Ahn D; Ciombor KK; Chen Z; Draper A
A phase I trial of trifluridine/tipiracil in combination with nanoliposomal irinotecan in advanced GI cancers
Volume: 32 Page(s): S200 - S200
07/03/2021 Authors: Alese O; Shaib W; Akce M; Diab M; Issa-Boube M; Ekundayo F; Wu C; El-Rayes B
Checkmate 040 Cohort 5: long-term efficacy and safety of nivolumab in patients with Child-Pugh B advanced hepatocellular carcinoma: associations between baseline biomarker analyses and outcomes
Volume: 75 Page(s): S243 - S244
07/01/2021 Authors: Matilla A; Sangro B; El-Khoureiry A; Santoro A; Melero I; Gracian AC; Rivera MA; Choo S-P; Kuromatsu R; El-Rayes B
Safety and Efficacy of 7 Days on/7 Days off Versus 14 Days on/7 Days off Schedules of Capecitabine in Patients with Metastatic Colorectal Cancer: A Retrospective Review.
Clin Colorectal Cancer Volume: 20 Page(s): 153 - 160
06/01/2021 Authors: Bryson E; Sakach E; Patel U; Watson M; Hall K; Draper A; Davis C; Goyal S; Alese O; Akce M
Survival Outcomes of Acinar Cell Pancreatic Cancer: A National Cancer Database Analysis.
Pancreas Volume: 50 Page(s): 529 - 536
04/01/2021 Authors: Shaib WL; Zakka K; Huang W; Chen Z; Alese OB; Wu C; Akce M; El-Rayes BF
Preliminary Safety, PK/PD, and Antitumor Activity of XmAb18087, an SSTR2 x CD3 Bispecific Antibody, in Patients With Advanced Neuroendocrine Tumors
Volume: 50 Page(s): 445 - 446
03/01/2021 Authors: El-Rayes B; Pant S; Villalobos V; Hendifar A; Chow W; Konda B; Reilley M; Benson A; Fisher G; Starr J
Is adjuvant chemotherapy beneficial for stage II-III goblet cell carcinoid/goblet cell adenocarcinoma of the appendix?
Surg Oncol Volume: 36 Page(s): 120 - 129
03/01/2021 Authors: Zakka K; Williamson S; Jiang R; Reid MD; Alese OB; Shaib WL; Wu C; Behera M; El-Rayes BF; Akce M
Perioperative therapy in metastatic colorectal cancer: Pattern of use and survival outcomes.
J Surg Oncol Volume: 123 Page(s): 596 - 605
02/01/2021 Authors: Alese OB; Zakka K; Huo X; Jiang R; Shaib WL; Akce M; Behera M; Sullivan P; Wu C; El-Rayes BF
Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody.
Am J Clin Oncol Volume: 44 Page(s): 74 - 81
02/01/2021 Authors: Akce M; Liu Y; Zakka K; Martini DJ; Draper A; Alese OB; Shaib WL; Wu C; Wedd JP; Sellers MT
Should Signet Ring Cell Histology Alter the Treatment Approach for Clinical Stage I Gastric Cancer?
Ann Surg Oncol Volume: 28 Page(s): 97 - 105
01/01/2021 Authors: Turgeon MK; Gamboa AC; Rupji M; Lee RM; Switchenko JM; El-Rayes BF; Russell MC; Cardona K; Kooby DA; Staley CA
Predictive and Prognostic Effects of Primary Tumor Size on Colorectal Cancer Survival.
Front Oncol Volume: 11 Page(s): 728076
01/01/2021 Authors: Alese OB; Zhou W; Jiang R; Zakka K; Huang Z; Okoli C; Shaib WL; Akce M; Diab M; Wu C
High-Risk Features Are Prognostic in dMMR/MSI-H Stage II Colon Cancer.
Front Oncol Volume: 11 Page(s): 755113
01/01/2021 Authors: Mohamed A; Jiang R; Philip PA; Diab M; Behera M; Wu C; Alese O; Shaib WL; Gaines TM; Balch GG
Impact of high-risk features for stage II adenocarcinoma of the appendix.
Volume: 27 Page(s): 100329
01/01/2021 Authors: Akce M; Zakka K; Penley M; Jiang R; Khalil L; Alese OB; Shaib WL; Wu C; Behera M; El-Rayes BF
Impact of Tumor Side on Clinical Outcomes in Stage II and III Colon Cancer With Known Microsatellite Instability Status.
Volume: 11 Page(s): 592351
01/01/2021 Authors: Akce M; Zakka K; Jiang R; Williamson S; Alese OB; Shaib WL; Wu C; Behera M; El-Rayes BF
Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer.
Mol Cancer Ther Volume: 20 Page(s): 150 - 160
01/01/2021 Authors: Zhang Y; Ware MB; Zaidi MY; Ruggieri AN; Olson BM; Komar H; Farren MR; Nagaraju GP; Zhang C; Chen Z
Variant anatomy of the biliary system as a cause of pancreatic and peri-ampullary cancers.
HPB (Oxford) Volume: 22 Page(s): 1675 - 1685
12/01/2020 Authors: Muraki T; Reid MD; Pehlivanoglu B; Gonzalez RS; Sekhar A; Memis B; Xue Y; Cheng J; Jang K-T; Mittal P
HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
Surg Oncol Volume: 35 Page(s): 460 - 465
12/01/2020 Authors: Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA
Orbital and Ocular Metastasis from Neuroendocrine Tumors: A Case Series
Volume: 113 Page(s): 673 - 673
12/01/2020 Authors: Zakka KM; Shaib W; Kucuk K; Wheeler S; Bergstrom C; El-Rayes B
Lymph Node Subcapsular Sinus Microenvironment-On-A-ChipModeling Shear Flow Relevant to Lymphatic Metastasis and Immune Cell Homing.
iScience Volume: 23 Page(s): 101751
11/20/2020 Authors: Birmingham KG; O'Melia MJ; Bordy S; Reyes Aguilar D; El-Reyas B; Lesinski G; Thomas SN
INVESTIGATING THE CLINICAL SAFETY, EFFICACY, AND IMMUNE MODULATION OF COMBINED XL888 AND PEMBROLIZUMAB IN METASTATIC GASTROINTESTINAL MALIGNANCIES
Volume: 8 Page(s): A202 - A203
11/01/2020 Authors: Herting C; Zhang Y; Doxie D; Farren M; Ware M; Alese O; Wu C; Shaib W; Akce M; Zaidi M
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.
JAMA Oncol Volume: 6 Page(s): e204564
11/01/2020 Authors: Yau T; Kang Y-K; Kim T-Y; El-Khoueiry AB; Santoro A; Sangro B; Melero I; Kudo M; Hou M-M; Matilla A
Frequency and clinicopathologic associations of DNA mismatch repair protein deficiency in ampullary carcinoma: Routine testing is indicated.
Cancer Volume: 126 Page(s): 4788 - 4799
11/01/2020 Authors: Xue Y; Balci S; Aydin Mericoz C; Taskin OC; Jiang H; Pehlivanoglu B; Muraki T; Memis B; Saka B; Kim GE
Suppressive myeloid cells are expanded by biliary tract cancer-derived cytokines in vitro and associate with aggressive disease.
Br J Cancer Volume: 123 Page(s): 1377 - 1386
10/01/2020 Authors: Ware MB; Zaidi MY; Yang J; Turgeon MK; Krasinskas A; Mace TA; Keenan K; Farren MR; Ruggieri AN; Li Y
Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma.
Br J Cancer Volume: 123 Page(s): 1228 - 1234
10/01/2020 Authors: Harvey RD; Carthon BC; Lewis C; Hossain MS; Zhang C; Chen Z; Harris WB; Alese OB; Shaib W; Bilen MA
Survival outcome of adjuvant chemotherapy in deficient mismatch repair stage III colon cancer.
Cancer Volume: 126 Page(s): 4136 - 4147
09/15/2020 Authors: Shaib WL; Zakka KM; Jiang R; Yan M; Alese OB; Akce M; Wu C; Behera M; El-Rayes BF
Morphologic Variants of Pancreatic Neuroendocrine Tumors: Clinicopathologic Analysis and Prognostic Stratification.
Endocr Pathol Volume: 31 Page(s): 239 - 253
09/01/2020 Authors: Xue Y; Reid MD; Pehlivanoglu B; Obeng RC; Jiang H; Memis B; Lui SK; Sarmiento J; Kooby D; Maithel SK
Mirage or long-awaited oasis: reinvigorating T-cell responses in pancreatic cancer.
J Immunother Cancer Volume: 8
08/01/2020 Authors: Ware MB; El-Rayes BF; Lesinski GB
Turning up the heat on pancreatic ductal adenocarcinoma via inhibiting vasoactive intestinal peptide signaling
Volume: 80
08/01/2020 Authors: Ravindranathan S; Ware B; Zaidi M; Zhu J; Dhamsania RK; Wang S; Li Y; Rao IH; Thomas SN; Lesinski GB
Pancreatic neuroendocrine tumors: Therapeutic challenges and research limitations.
World J Gastroenterol Volume: 26 Page(s): 4036 - 4054
07/28/2020 Authors: Mpilla GB; Philip PA; El-Rayes B; Azmi AS
Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancer.
Cancer Volume: 126 Page(s): 3360 - 3371
07/15/2020 Authors: Nagaraju GP; Farran B; Farren M; Chalikonda G; Wu C; Lesinski GB; El-Rayes BF
Radiation as a Single-Modality Treatment in Localized Pancreatic Cancer.
Pancreas Volume: 49 Page(s): 822 - 829
07/01/2020 Authors: Shaib WL; Zakka K; Shahin AA; Yared F; Switchenko JM; Wu C; Akce M; Alese OB; Patel PR; Mcdonald M
A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors.
Clin Cancer Res Volume: 26 Page(s): 2497 - 2505
06/01/2020 Authors: Owonikoko TK; Harvey RD; Carthon B; Chen Z; Lewis C; Collins H; Zhang C; Lawson DH; Alese OB; Bilen MA
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer Living With HIV: A Perspective on Recent Progress and Future Needs.
JCO Oncol Pract Volume: 16 Page(s): 319 - 325
06/01/2020 Authors: Sahin IH; Kane SR; Brutcher E; Guadagno J; Smith KE; Wu C; Lesinski GB; Gunthel CJ; El-Rayes BF
Adjuvant concurrent chemoradiotherapy in extrahepatic cholangiocarcinoma.
Volume: 38
05/20/2020 Authors: Shaib WL; Zakka KM; Tian F; Chen Z; Patel PR; Lin JY; Wu C; Akce M; Alese OB; El-Rayes BF
Blood-based next-generation sequencing analysis of neuroendocrine neoplasms.
Oncotarget Volume: 11 Page(s): 1749 - 1757
05/12/2020 Authors: Zakka K; Nagy R; Drusbosky L; Akce M; Wu C; Alese OB; El-Rayes BF; Kasi PM; Mody K; Starr J
In-hospital 30-day mortality for older patients with pancreatic cancer undergoing pancreaticoduodenectomy.
J Geriatr Oncol Volume: 11 Page(s): 660 - 667
05/01/2020 Authors: Shaib WL; Zakka K; Hoodbhoy FN; Belalcazar A; Kim S; Cardona K; Russell MC; Maithel SK; Sarmiento JM; Wu C
High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study.
Oncologist Volume: 25 Page(s): e877
05/01/2020 Authors: Alese OB; Jiang R; Shaib W; Wu C; Akce M; Behera M; El-Rayes BF
Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers.
Oncologist Volume: 25 Page(s): 414 - 421
05/01/2020 Authors: Shaib WL; Zakka K; Staley C; Roberts A; Akce M; Wu C; Alese OB; El-Rayes BF
STAT3 Inhibition for Gastroenteropancreatic Neuroendocrine Tumors: Potential for a New Therapeutic Target?
J Gastrointest Surg Volume: 24 Page(s): 1138 - 1148
05/01/2020 Authors: Lopez-Aguiar AG; Postlewait LM; Ethun CG; Zaidi MY; Zhelnin K; Krasinskas A; Russell MC; Kooby DA; Cardona K; El-Rayes BF
Young Adults With Pancreatic Cancer: National Trends in Treatment and Outcomes.
Pancreas Volume: 49 Page(s): 341 - 354
03/01/2020 Authors: Alese OB; Jiang R; Shaib W; Wu C; Akce M; Gaines T; Ni L; Behera M; El-Rayes BF
Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy.
Oncologist Volume: 25 Page(s): e528 - e535
03/01/2020 Authors: Bilen MA; Martini DJ; Liu Y; Shabto JM; Brown JT; Williams M; Khan AI; Speak A; Lewis C; Collins H
Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials.
Cancer Volume: 126 Page(s): 575 - 582
02/01/2020 Authors: Martini DJ; Kline MR; Liu Y; Shabto JM; Williams MA; Khan AI; Lewis C; Collins H; Akce M; Kissick HT
Clinicopathological features and survival outcomes of rare histologic variants of gallbladder cancer.
J Surg Oncol Volume: 121 Page(s): 294 - 302
02/01/2020 Authors: Akce M; Zakka K; Penley M; Jiang R; Alese OB; Shaib WL; Wu C; Behera M; El-Rayes BF
The impact of inflammatory biomarkers, BMI, and sarcopenia on survival in advanced hepatocellular carcinoma treated with immunotherapy
Volume: 38
02/01/2020 Authors: Akce M; Liu Y; Zakka KM; Martini DJ; Draper A; Alese OB; Shaib WL; Wu C; Wedd J; Sellers MT
Clinical and molecular markers of immune checkpoint inhibitor (ICI) response in dMMR colorectal cancer (CRC) patients (pts)
Volume: 38
02/01/2020 Authors: Sahin IH; Goyal S; Pumpalova YS; Sonbol MB; Das S; Haraldsdottir S; Chen Z; Akce M; Alese OB; Shaib WL
Is adjuvant chemotherapy beneficial for stage II-III goblet cell tumors of the appendix?
Volume: 38
02/01/2020 Authors: Zakka KM; Williamson S; Jiang R; Alese OB; Shaib WL; Wu C; Behera M; El-Rayes BF; Akce M
Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy.
JCI Insight Volume: 5
01/16/2020 Authors: Farren MR; Sayegh L; Ware MB; Chen H-R; Gong J; Liang Y; Krasinskas A; Maithel SK; Zaidi M; Sarmiento JM
Survival outcomes in patients with gastric and gastroesophageal junction adenocarcinomas treated with perioperative chemotherapy with or without preoperative radiotherapy.
Cancer Volume: 126 Page(s): 37 - 45
01/01/2020 Authors: Tian S; Jiang R; Madden NA; Ferris MJ; Buchwald ZS; Xu KM; Cardona K; Maithel SK; McDonald MW; Lin JY
Correlation Patterns Among B7 Family Ligands and Tryptophan Degrading Enzymes in Hepatocellular Carcinoma.
Front Oncol Volume: 10 Page(s): 1632
01/01/2020 Authors: Chinnadurai R; Scandolara R; Alese OB; Arafat D; Ravindranathan D; Farris AB; El-Rayes BF; Gibson G
Handbook of Gastrointestinal Cancers Evidence-Based Treatment and Multidisciplinary Patient Care Preface
Page(s): XVII - XVII
01/01/2020 Authors: Bekaii-Saab T; El-Rayes BF; Pawlik TM
Nonbacterial Thrombotic Endocarditis and Widespread Skin Necrosis in Newly Diagnosed Lung Adenocarcinoma.
Case Rep Oncol Volume: 13 Page(s): 239 - 244
01/01/2020 Authors: Zakka K; Zakka P; Davarpanah A; Koshkelashvili N; Bilen MA; Owonikoko T; El-Rayes B; Akce M
Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy.
Oncologist
12/05/2019 Authors: Bilen MA; Martini DJ; Liu Y; Shabto JM; Brown JT; Williams M; Khan AI; Speak A; Lewis C; Collins H
IL-6 regulates CTLA4 expression on CD4+T-cells and dual antibody blockade of IL-6 and CTLA4 leads to tumor regression in an orthotopic murine model of pancreatic ductal adenocarcinoma
Volume: 79
12/01/2019 Authors: Ware MB; McQuinn C; Mace TA; Bowers J; Shakya R; Farris B; Young G; Carson WE; Paulos CM; El-Rayes B
Pancreatic stellate cells promote pancreatic cancer invasion and metastasis by secretion of soluble factors and through contact-mediated mechanisms
Volume: 79
12/01/2019 Authors: Ware MB; Yue J; El-Rayes B; Maithel SK; Sarmiento J; Lesinski GB
Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials.
Invest New Drugs Volume: 37 Page(s): 1198 - 1206
12/01/2019 Authors: Martini DJ; Liu Y; Shabto JM; Lewis C; Kline MR; Collins H; Akce M; Kissick HT; Carthon BC; Shaib WL
Analysis of racial disparities in the treatment and outcomes of colorectal cancer in young adults.
Cancer Epidemiol Volume: 63 Page(s): 101618
12/01/2019 Authors: Alese OB; Jiang R; Zakka KM; Wu C; Shaib W; Akce M; Behera M; El-Rayes BF
Clinical Outcomes of Small Bowel Adenocarcinoma.
Volume: 18 Page(s): 257 - 268
12/01/2019 Authors: Akce M; Jiang R; Zakka K; Wu C; Alese OB; Shaib WL; Behera M; El-Rayes BF
PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors.
Cancers (Basel) Volume: 11
11/29/2019 Authors: Mpilla G; Aboukameel A; Muqbil I; Kim S; Beydoun R; Philip PA; Mohammad RM; Kamgar M; Shidham V; Senapedis W
Vasoactive intestinal peptide: a novel checkpoint pathway in pancreatic ductal adenocarcinoma
Volume: 7
11/06/2019 Authors: Ravindranathan S; Wang S; Ware B; Zaidi M; Zhu J; Dhamsania R; Thomas S; Li Y; El-rayes B; Lesinski G
Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer.
Oncologist Volume: 24 Page(s): 1453 - 1461
11/01/2019 Authors: Morse MA; Overman MJ; Hartman L; Khoukaz T; Brutcher E; Lenz H-J; Atasoy A; Shangguan T; Zhao H; El-Rayes B
A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction.
Br J Clin Pharmacol Volume: 85 Page(s): 2499 - 2511
11/01/2019 Authors: Takebe N; Beumer JH; Kummar S; Kiesel BF; Dowlati A; O'Sullivan Coyne G; Piekarz R; Rubinstein L; Fogli LK; Vaishampayan U
Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms.
Br J Cancer Volume: 121 Page(s): 809 - 818
11/01/2019 Authors: Sahin IH; Akce M; Alese O; Shaib W; Lesinski GB; El-Rayes B; Wu C
CHECKMATE 040: EFFICACY, HEPATIC SAFETY, AND BIOMARKERS OF NIVOLUMAB plus IPILIMUMAB COMBINATION THERAPY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
Volume: 70 Page(s): 131A - 132A
10/01/2019 Authors: Sangro B; Hsu C; Kang Y-K; Kim T-Y; El-Khoueiry A; Santoro A; Melero I; Kudo M; Hou M-M; Pena AM
Phase Ib trial of gemcitabine with yttrium-90 in patients with hepatic metastasis of pancreatobiliary origin.
J Gastrointest Oncol Volume: 10 Page(s): 944 - 956
10/01/2019 Authors: Nezami N; Camacho JC; Kokabi N; El-Rayes BF; Kim HS
Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer.
Int J Cancer Volume: 145 Page(s): 1529 - 1537
09/15/2019 Authors: Nagaraju GP; Zakka KM; Landry JC; Shaib WL; Lesinski GB; El-Rayes BF
Effect of Neoadjuvant SBRT or Chemoradiation on Nodal Positivity for Resected Pancreatic Adenocarcinoma
Volume: 105 Page(s): E237 - E238
09/01/2019 Authors: Jiang C; Rupji M; Goyal S; Liu Y; Tanenbaum DG; Xu KM; Shaib W; El-rayes B; Sarmiento J; Maithel SK
The Effect of Neoadjuvant Radiotherapy on Tumor Regression Grade in Resected Pancreatic Adenocarcinoma
Volume: 105 Page(s): E241 - E242
09/01/2019 Authors: Patel PR; Jiang C; Xu KM; Tanenbaum DG; Rupji M; Krasinskas A; El-rayes B; Shaib W; Alese O; Sarmiento J
Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy.
BMC Cancer Volume: 19 Page(s): 857
08/29/2019 Authors: Bilen MA; Shabto JM; Martini DJ; Liu Y; Lewis C; Collins H; Akce M; Kissick H; Carthon BC; Shaib WL
National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer.
Cancer Volume: 125 Page(s): 2732 - 2746
08/15/2019 Authors: George TJ; Franke AJ; Chakravarthy AB; Das P; Dasari A; El-Rayes BF; Hong TS; Kinsella TJ; Landry JC; Lee JJ
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis.
J Natl Cancer Inst Volume: 111 Page(s): 782 - 794
08/01/2019 Authors: Janssen QP; Buettner S; Suker M; Beumer BR; Addeo P; Bachellier P; Bahary N; Bekaii-Saab T; Bali MA; Besselink MG
Induction Therapy in Localized Pancreatic Cancer.
Pancreas Volume: 48 Page(s): 913 - 919
08/01/2019 Authors: Shaib WL; Sayegh L; Zhang C; Belalcazar A; Ip A; Alese OB; Akce M; Wu C; Qu Y; Maithel SK
High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study.
Oncologist Volume: 24 Page(s): 911 - 920
07/01/2019 Authors: Alese OB; Jiang R; Shaib W; Wu C; Akce M; Behera M; El-Rayes BF
Targeting vasoactive intestinal peptide signaling to enhance pancreatic cancer responsiveness to immunotherapy
Volume: 79
07/01/2019 Authors: Ravindranathan S; Li Y; Wang S; Zaidi MY; Lesinski GB; El-Rayes B; Waller EK
DNA-PKCS deacetylation by SIRT2 promotes DNA double-strand break repair by non-homologous end joining
CANCER RESEARCH Volume: 79
07/01/2019 Authors: Head PE; Ganji NP; Wang S-Y; Duong D; Zhang H; Daddacha W; Li S; Seyfried NT; Smalley DM; Wang Y
Targeted hyaluronic acid nanoparticles improve treatment response in pancreatic cancer
Volume: 79
07/01/2019 Authors: Jajja MR; Zhu L; Wang D; Staley CA; El-Rayes B; Kooby DA; Yang L
Comparison of neoadjuvant FOLFIRINOX alone vs FOLFIRINOX plus stereotactic body radiation as immune-modulators of the pancreatic adenocarcinoma microenvironment
Volume: 79
07/01/2019 Authors: Farren MR; Shaib W; Zaidi M; Sayegh L; Kooby D; Maithel S; Krasinskas A; Alese O; Sarmiento J; El-Rayes B
Heat shock protein 90 inhibitors alter pancreatic stellate cell cytokine production and enhances the efficacy of immune checkpoint blockade in pancreatic cancer
Volume: 79
07/01/2019 Authors: Zaidi M; Zhang Y; Ware MB; Farren MR; Komar H; Olson B; Nagaraju GP; Akce M; Alese O; Maithel S
BBI-608 modulates DNA repair pathways, induces apoptosis and impacts response to 5-Fluorouracil and ionizing radiation in pancreatic cancer cells
Volume: 79
07/01/2019 Authors: Farran B; Nagaraju GP; Shipra SG; Bethi SR; Lesinski GB; El-Rayes B
BBI-608 enhances the activity of chemoradiotherapy in colorectal cancer pre-clinical models
Volume: 79
07/01/2019 Authors: Nagaraju GP; Balney R; Bethi SR; Govardhanagiri S; Lesinski GBLB; El-Rayes BF
Interaction of STAT proteins with genistein: A computational analysis
Volume: 79
07/01/2019 Authors: Govardhanagiri S; Bethi SR; Saddala MS; El-Rayes BF; Nagaraju GP
Curcumin analogs: Their roles in pancreatic cancer growth and metastasis.
Int J Cancer Volume: 145 Page(s): 10 - 19
07/01/2019 Authors: Nagaraju GP; Benton L; Bethi SR; Shoji M; El-Rayes BF
Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results.
J Gastrointest Cancer Volume: 50 Page(s): 269 - 275
06/01/2019 Authors: Mohamed A; Twardy B; AbdAllah N; Akhras A; Ismail H; Zordok M; Schrapp K; Attumi T; Tesfaye A; El-Rayes B
Derazantinib (DZB) provides antitumor efficacy regardless of line of therapy in patients (pts) with FGFR2-fusion positive advanced intrahepatic cholangiocarcinoma (iCCA).
Volume: 37
05/20/2019 Authors: Busset MDD; El-Rayes BF; Harris WP; Damjanov N; Masi G; Rimassa L; Bhoori S; Niger M; Personeni N; Braiteh FS
Personalized T cell therapy for metastatic colon cancer.
Volume: 37
05/20/2019 Authors: Ravindranathan S; Jajja MR; Waller A; Bommireddy R; Petersen C; Selvaraj P; Yang L; Lesinski GB; El-Rayes BF; Flynn B
Blood-based next-generation sequencing analysis of neuroendocrine tumors.
Volume: 37
05/20/2019 Authors: Shaib WL; Roberts A; Zakka KM; Akce M; Wu C; Alese OB; El-Rayes BF; Kasi PM; Starr JS
Perioperative therapy in patients with metastatic colorectal cancer.
Volume: 37
05/20/2019 Authors: Alese OB; Zakka KM; Huo X; Jiang R; Shaib WL; Wu C; Akce M; Sullivan PS; Behera M; El-Rayes BF
Vasoactive intestinal peptide signaling - a novel immune checkpoint in pancreatic ductal adenocarcinoma
Volume: 202
05/01/2019 Authors: Ravindranathan S; Li Y; Wang S; Zaidi M; Lesinski GB; El-Rayes B; Waller EK
Cyclooxygenase-2 in gastrointestinal malignancies.
Cancer Volume: 125 Page(s): 1221 - 1227
04/15/2019 Authors: Nagaraju GP; El-Rayes BF
Efficacy and hepatic safety of nivolumab treatment in patients with Child-Pugh B disease and advanced hepatocellular carcinoma in CheckMate 040
Volume: 70 Page(s): E619 - E619
04/01/2019 Authors: Sangro B; Matilla AM; Santoro A; Melero I; Cubillo Gracian A; Rivera Acosta M; Choo S-P; El-Khoureiry A; Kuromatsu R; El-Rayes B
Phase IB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy, Carboplatin, and Everolimus in Patients With Locally Advanced Esophageal Cancer.
Am J Clin Oncol Volume: 42 Page(s): 331 - 336
04/01/2019 Authors: Saba NF; Force S; Staley C; Fernandez F; Willingham F; Pickens A; Cardona K; Chen Z; Goff L; Cardin D
Pancreatic Cancer and Immunotherapy: Resistance Mechanisms and Proposed Solutions.
J Gastrointest Cancer Volume: 50 Page(s): 1 - 8
03/01/2019 Authors: Tan E; El-Rayes B
Autotaxin determines colitis severity in mice and is secreted by B cells in the colon.
FASEB J Volume: 33 Page(s): 3623 - 3635
03/01/2019 Authors: Lin S; Haque A; Raeman R; Guo L; He P; Denning TL; El-Rayes B; Moolenaar WH; Yun CC
Nonsurgical Management of Rectal Cancer.
J Oncol Pract Volume: 15 Page(s): 123 - 131
03/01/2019 Authors: Akce M; El-Rayes BF
Clinical outcomes of hepatocellular carcinoma variants compared to hepatocellular carcinoma.
Volume: 37
02/01/2019 Authors: Zakka KM; Jiang R; Alese OB; Shaib WL; Wu C; Wedd J; Sellers MT; Behera M; El-Rayes BF; Akce M
Genomic alterations in appendiceal carcinoma using circulating DNA.
Volume: 37
02/01/2019 Authors: Shaib WL; Roberts A; Akce M; Wu C; Alese OB; El-Rayes BF
Impact of genomic alterations (GAs) on outcomes and their distribution by age groups in metastatic colorectal cancer (mCRC) patients (pts)
Volume: 37
02/01/2019 Authors: Sahin IH; Chen WH; Chen Z; Akce M; Alese OB; Shaib WL; El-Rayes BF; Wu C
Phase II randomized, double-blind, study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients hcrn GI14-198.
Volume: 37
02/01/2019 Authors: Shaib WL; O'Neil B; El-Rayes BF; Cohen SJ; Khair TA; Robin EL; Huyck TK; Redman RA; Sama AR; Kassar M
Sequential immunotherapy and association with clinical outcomes in advanced-stage cancer patients
Volume: 7
02/01/2019 Authors: Bilen M; Martini D; Liu Y; Lewis C; Collins H; Shabto J; Akce M; Kissick H; Carthon B; Shaib W
Gastric squamous cell carcinoma and gastric adenosquamous carcinoma, clinical features and outcomes of rare clinical entities: a National Cancer Database (NCDB) analysis.
J Gastrointest Oncol Volume: 10 Page(s): 85 - 94
02/01/2019 Authors: Akce M; Jiang R; Alese OB; Shaib WL; Wu C; Behera M; El-Rayes BF
Tumor Penetrating Polymeric Nanoparticle Improves Response in a Drug Resistant Pancreatic Cancer PDX Model
Volume: 26 Page(s): S6 - S7
02/01/2019 Authors: Jajja M; Zhu L; Wang D; Staley C; El-Rayes B; Kooby DA; Yang L
TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial.
JMIR Res Protoc Volume: 8 Page(s): e11545
01/17/2019 Authors: Chauhan N; Mulcahy MF; Salem R; Benson Iii AB; Boucher E; Bukovcan J; Cosgrove D; Laframboise C; Lewandowski RJ; Master F
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.
Br J Cancer Volume: 120 Page(s): 165 - 171
01/01/2019 Authors: Mazzaferro V; El-Rayes BF; Droz Dit Busset M; Cotsoglou C; Harris WP; Damjanov N; Masi G; Rimassa L; Personeni N; Braiteh F
Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma.
J Hepatocell Carcinoma Volume: 6 Page(s): 119 - 129
01/01/2019 Authors: Zakka K; Jiang R; Alese OB; Shaib WL; Wu C; Wedd JP; Sellers MT; Behera M; El-Rayes BF; Akce M
Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer.
Cancer Volume: 125 Page(s): 57 - 67
01/01/2019 Authors: Shaib WL; Narayan AS; Switchenko JM; Kane SR; Wu C; Akce M; Alese OB; Patel PR; Maithel SK; Sarmiento JM
Racial Disparities, Outcomes, and Surgical Utilization among Hispanics with Esophageal Cancer: A Surveillance, Epidemiology, and End Results Program Database Analysis.
Oncology Volume: 97 Page(s): 49 - 58
01/01/2019 Authors: Gupta DR; Liu Y; Jiang R; Walid S; Higgins K; Landry J; McDonald M; Willingham FF; El-Rayes BF; Saba NF
The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy.
Cancer Volume: 125 Page(s): 127 - 134
01/01/2019 Authors: Bilen MA; Martini DJ; Liu Y; Lewis C; Collins HH; Shabto JM; Akce M; Kissick HT; Carthon BC; Shaib WL
Comparative proteogenomic analysis of right-sided colon cancer, left-sided colon cancer and rectal cancer reveals distinct mutational profiles.
Mol Cancer Volume: 17 Page(s): 177
12/21/2018 Authors: Imperial R; Ahmed Z; Toor OM; Erdoan C; Khaliq A; Case P; Case J; Kennedy K; Cummings LS; Melton N
Nivolumab in Patients with Child-Pugh B Advanced Hepatocellular Carcinoma (aHCC) in the CheckMate-040 Study
Volume: 68 Page(s): 1445A - 1446A
12/01/2018 Authors: Kudo M; Matilla AM; Santoro A; Melero I; Cubillo Gracian A; Rivera Acosta M; Choo SP; El-Khoueiry A; Kuromatsu R; El Rayes B
Pilot Study of Potential Activation of c-MYC by Aurora Kinase A in Everolimus-Resistant Localized Esophageal Cancer Treated with XELOX followed by Carboplatin/Radiation
Volume: 102 Page(s): E27 - E27
11/01/2018 Authors: Saba NF; Force S; Staley CA; Fernandez F; Willingham FF; Pickens A; Cardona K; Chen Z; Goff L; Cardin D
Apoptosis-Inducing Effect of Erlotinib Is Potentiated by 3,3 '-Diindolylmethane In Vitro and In Vivo Using an Orthotopic Model of Pancreatic Cancer (Retraction of Vol 7, Pg 1708, 2008)
MOLECULAR CANCER THERAPEUTICS Volume: 17 Page(s): 2266 - 2266
10/01/2018 Authors: Ali S; Banerjee S; Ahmad A; El-Rayes BF; Philip PA; Sarkar FH
Sarcopenia and inflammation predicts survival in advanced stage cancer patients (pts) treated with immunotherapy (IO).
Volume: 29 Suppl 8 Page(s): viii42
10/01/2018 Authors: Bilen MA; Martini DJ; Shabto JM; Liu Y; Khan AI; Williams MA; Lewis C; Collins HH; Kissick H; Carthon BC
The Epidemiology of Esophageal Adenocarcinoma in the United States
Volume: 113 Page(s): S185 - S186
10/01/2018 Authors: Hang T-VP; Spiritos Z; Gamboa A; Chen Z; Force S; Keilin S; Saba N; El-Rayes B; Cai Q; Willingham F
Potentiation of the Effect of Erlotinib by Genistein in Pancreatic Cancer: The Role of Akt and Nuclear Factor-kappa B (Retraction of Vol 66, Pg 10553, 2006)
CANCER RESEARCH Volume: 78 Page(s): 5472 - 5472
09/15/2018 Authors: El-Rayes BF; Philip PA; Abbruzzese J; Sarkar FH; Ali S; Ali IF
Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.
Cancer Volume: 124 Page(s): 3118 - 3126
08/01/2018 Authors: Sanoff HK; Goldberg RM; Ivanova A; O'Reilly S; Kasbari SS; Kim RD; McDermott R; Moore DT; Zamboni W; Grogan W
Blood based biomarkers and association with clinical outcome (CO) in advanced stage patients (pts) treated with immunotherapy (IO)
Volume: 78
07/01/2018 Authors: Martini DJ; Liu Y; Lewis C; Collins H; Akce M; Kissick H; Carthon BC; Shaib WL; Alese OB; Pillai R
Derazantinib (ARQ 087) pharmacodynamics: Alterations in FGF19/21/23 and phosphate in patients with cholangiocarcinoma
Volume: 78
07/01/2018 Authors: Hall T; Mazzaferro V; El-Rayes B; Cotsoglou C; Harris WP; Damjanov N; Masi G; Rimassa L; Personeni N; Zagonel V
Inhibition of Hsp90 sensitizes pancreatic cancer in vitro and in vivo to chemo-radiotherapy
Volume: 78
07/01/2018 Authors: Nagaraju GP; El-Rayes BF
Evaluation of Treatment Patterns and Survival Outcomes in Elderly Pancreatic Cancer Patients: A Surveillance, Epidemiology, and End Results-Medicare Analysis.
Oncologist Volume: 23 Page(s): 704 - 711
06/01/2018 Authors: Shaib WL; Jones JS; Goodman M; Sarmiento JM; Maithel SK; Cardona K; Kane S; Wu C; Alese OB; El-Rayes BF
Investigational agents to enhance the efficacy of chemotherapy or radiation in pancreatic cancer.
Crit Rev Oncol Hematol Volume: 126 Page(s): 201 - 207
06/01/2018 Authors: Hurtado M; Sankpal UT; Ranjan A; Maram R; Vishwanatha JK; Nagaraju GP; El-Rayes BF; Basha R
A Phase II multi institutional study of nivolumab in patients with advanced refractory biliary tract cancers (BTC).
Volume: 29 Suppl 5 Page(s): v103
06/01/2018 Authors: Kim R; Kim D; Alese O; Li D; El-Rayes B; Shah N; Schell M; Zhou J; Chung V
Survival outcomes in gastric and gastroesophageal junction adenocarcinoma treated with peri-operative chemotherapy with or without pre-operative radiotherapy.
Volume: 36
05/20/2018 Authors: Tian S; Jiang R; Madden NA; Ferris MJ; Buchwald Z; Xu KM; Cardona K; Maithel S; McDonald MW; Lin JY
Neoadjuvant FOLFIRINOX in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis.
Volume: 36
05/20/2018 Authors: Janssen Q; Buettner S; Suker M; Margonis GA; Paniccia A; El-Rayes BF; Bahary N; Chau I; Hosein PJ; Ko AH
Adjuvant treatment for resected sub-centimeter T1 pancreatic cancer.
Volume: 36
05/20/2018 Authors: Shaib WL; Naranyan AS; Switchenko JM; Akce M; Sarmiento J; Maithel S; Kooby DA; Patel PR; Cardona K; Alese OB
Early change in blood-based biomarkers and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO)
Volume: 36
05/20/2018 Authors: Martini DJ; Liu Y; Lewis CM; Shabto JM; Akce M; Kissick H; Carthon BC; Shaib WL; Alese OB; Pillai RN
A phase I/II study of trifluridine/tipiracil (TAS-102) in combination with nanoliposomal irinotecan (NAL-IRI) in advanced GI cancers.
Volume: 36
05/20/2018 Authors: Alese OB; Shaib WL; Akce M; Wu C; El-Rayes BF
Incidence, treatment and survival outcomes of small bowel adenocarcinomas: A National Cancer Database (NCDB) analysis.
Volume: 36
05/20/2018 Authors: Akce M; Jiang R; Wu C; Alese OB; Shaib WL; Behera M; El-Rayes BF
Retrospective study of the safety of administering pegfilgrastim on the same day of 5-Fluorouracil pump disconnect.
Volume: 36
05/20/2018 Authors: Patel N; Wu C; Draper A; LaFollette JA; Brutcher E; El-Rayes BF; Alese OB; Shaib WL; Akce M; Chen Z
Impact of adjuvant chemotherapy in higher risk stage II colon cancer with a deficient mismatch repair (dMMR)/ microsatellite instability-high (MSI-H) profile.
Volume: 36
05/20/2018 Authors: Mohamed AMR; Jiang R; Philip PA; Diab M; Behera M; Wu C; El-Rayes BF; Akce M
Altering the cytokine profile in the pancreatic cancer microenvironment with heat shock protein-90 inhibitors to enhance immunotherapy.
Volume: 200
05/01/2018 Authors: Lesinski GB; Zhang Y; Farren MR; Komar H; Ware B; Olson B; Zaidi M; Nagaraju GP; Akce M; Alese OB
A patient-centered team approach in oncology.
Cancer Volume: 124 Page(s): 1856 - 1858
05/01/2018 Authors: Wu CS; El-Rayes BF
Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases.
Cancer Volume: 124 Page(s): 1992 - 2000
05/01/2018 Authors: Kim HS; Shaib WL; Zhang C; Nagaraju GP; Wu C; Alese OB; Chen Z; Brutcher E; Renfroe M; El-Rayes BF
Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer.
Cancer Chemother Pharmacol Volume: 81 Page(s): 659 - 670
04/01/2018 Authors: El-Khoueiry AB; Sarantopoulos J; O'Bryant CL; Ciombor KK; Xu H; O'Gorman M; Chakrabarti J; Usari T; El-Rayes BF
Chemotherapy with or Without Definitive Radiation Therapy in Inoperable Pancreatic Cancer.
Ann Surg Oncol Volume: 25 Page(s): 1026 - 1033
04/01/2018 Authors: Zhong J; Switchenko J; Behera M; Kooby D; Maithel SK; McDonald MW; Lin JY; Cassidy RJ; El-Rayes B; Landry J
Adenocarcinoma Ex-Goblet Cell Carcinoid Is Not aNeuroendocrine Neoplasm: Immunoprofiling of 60 Cases Further Establishes Its Identity As a Distinct (Appendiceal Type) of Adenocarcinoma
Volume: 98 Page(s): 297 - 297
03/01/2018 Authors: Reid M; Pehlivanoglu B; Xue Y; Memis B; Robinson B; Toussaint MA; Krasinskas A; Staley C; El-Rayes B; Mogal H
Adenocarcinoma Ex-Goblet Cell Carcinoid Is Not aNeuroendocrine Neoplasm: Immunoprofiling of 60 Cases Further Establishes Its Identity As a Distinct (Appendiceal Type) of Adenocarcinoma
Volume: 31 Page(s): 297 - 297
03/01/2018 Authors: Reid M; Pehlivanoglu B; Xue Y; Memis B; Robinson B; Toussaint MA; Krasinskas A; Staley C; El-Rayes B; Mogal H
Growth Pattern Of Invasive Ampullary Carcinomas As Demarcated Versus Infitlrative Has Significant Prognostic Correlation; A Clinicopathologic Analysis Of 257 Cases
Volume: 31 Page(s): 313 - 314
03/01/2018 Authors: Xue Y; Pehlivanoglu B; Reid M; Krasinskas A; Balci S; Kim G; Davis D; Liu H; Peng L; Tajiri T
Low Union (Lower Insertion of Cystic Duct into Common Hepatic Duct) as a Major Etiologic Factor in the Development of Pancreatic, Distal Bile Duct and Ampullary Cancers: An analysis of 860 pancreatobiliary resections
Volume: 31 Page(s): 684 - 685
03/01/2018 Authors: Muraki T; Reid M; Gonzalez RS; Sekhar A; Memis B; Pehlivanoglu B; Xue Y; Mittal P; Sarmiento JM; Kooby D
Low Union (Lower Insertion of Cystic Duct into Common Hepatic Duct) as a Major Etiologic Factor in the Development of Pancreatic, Distal Bile Duct and Ampullary Cancers: An analysis of 860 pancreatobiliary resections
Volume: 98 Page(s): 684 - 685
03/01/2018 Authors: Muraki T; Reid M; Gonzalez RS; Sekhar A; Memis B; Pehlivanoglu B; Xue Y; Mittal P; Sarmiento JM; Kooby D
Growth Pattern Of Invasive Ampullary Carcinomas As Demarcated Versus Infitlrative Has Significant Prognostic Correlation; A Clinicopathologic Analysis Of 257 Cases
Volume: 98 Page(s): 313 - 314
03/01/2018 Authors: Xue Y; Pehlivanoglu B; Reid M; Krasinskas A; Balci S; Kim G; Davis D; Liu H; Peng L; Tajiri T
STAT3 inhibition for gastroenteropancreatic neuroendocrine tumors: Potential for a new therapeutic target?
Volume: 36
02/01/2018 Authors: Lopez-Aguiar AG; Postlewait LM; Zaidi M; Zhelnin K; Krasinskas A; Russell MC; Kooby DA; Cardona K; El-Rayes BF; Maithel S
Resection of pancreatic cancer following induction chemotherapy.
Volume: 36
02/01/2018 Authors: Shaib WL; Sayegh L; Alese O; Maithel S; Cardona K; Sarmiento J; Belalcazar A; Ip A; Qu Y; Akce M
Epidemiology and treatment of high-grade gastrointestinal neuroendocrine tumors (HG-GI-NETs)
Volume: 36
02/01/2018 Authors: Alese OB; Jiang R; Shaib WL; Wu CS-Y; Akce M; Behera M; El-Rayes BF
Phase Ib trial of pembrolizumab and XL888 in patients with advanced gastrointestinal malignancies.
Volume: 36
02/01/2018 Authors: Akce M; Alese OB; Shaib WL; Wu CS-Y; Lesinski GB; El-Rayes BF
The Potential of CAR T Cell Therapy in Pancreatic Cancer.
Front Immunol Volume: 9 Page(s): 2166
01/01/2018 Authors: Akce M; Zaidi MY; Waller EK; El-Rayes BF; Lesinski GB
Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials.
Oncology Volume: 95 Page(s): 138 - 146
01/01/2018 Authors: Owonikoko TK; Busari AK; Kim S; Chen Z; Akintayo A; Lewis C; Carthon BC; Alese OB; El-Rayes BF; Ramalingam SS
Appendiceal Mucinous Neoplasms: Diagnosis and Management.
Oncologist Volume: 23 Page(s): 137
01/01/2018 Authors: Shaib WL; Assi R; Shamseddine A; Alese OB; Staley C; Memis B; Adsay V; Bekaii-Saab T; El-Rayes BF
Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease.
Ann Surg Oncol Volume: 25 Page(s): 290 - 298
01/01/2018 Authors: Lopez-Aguiar AG; Ethun CG; Postlewait LM; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Sarmiento JM; Kooby DA; Staley CA
Inhibiting heat shock protein 90 and the ubiquitin-proteasome pathway impairs metabolic homeostasis and leads to cell death in human pancreatic cancer cells.
Cancer Volume: 123 Page(s): 4924 - 4933
12/15/2017 Authors: Belalcazar A; Shaib WL; Farren MR; Zhang C; Chen Z; Yang L; Lesinski GB; El-Rayes BF; Nagaraju GP
Incidence and Survival of Appendiceal Mucinous Neoplasms: A SEER Analysis.
Am J Clin Oncol Volume: 40 Page(s): 569 - 573
12/01/2017 Authors: Shaib WL; Goodman M; Chen Z; Kim S; Brutcher E; Bekaii-Saab T; El-Rayes BF
A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours.
Br J Cancer Volume: 117 Page(s): 1592 - 1599
11/21/2017 Authors: Papadopoulos KP; El-Rayes BF; Tolcher AW; Patnaik A; Rasco DW; Harvey RD; LoRusso PM; Sachdev JC; Abbadessa G; Savage RE
Combined IL-6 and CTLA4 blockade enhances CD8+T cell infiltration via CXCR3 and limits growth of pancreatic cancer in murine models
Volume: 5
11/07/2017 Authors: McQuinn C; Farren M; Mace T; Bowers J; Shakya R; Ferris AB; Young G; Carson W; Paulos C; El-Rayes B
Optimal Treatment Phase Selection Based on a 4DCT Deformable Registration for Stereotactic Body Radiation Therapy in Pancreatic Cancer
Volume: 99 Page(s): E743 - E743
10/01/2017 Authors: Yang X; Wang T; Liu T; Zhu L; Khan MK; El-Rayes B; Curran WJ; Landry JC
Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base.
Cancer Volume: 123 Page(s): 3476 - 3485
09/15/2017 Authors: Naik KB; Liu Y; Goodman M; Gillespie TW; Pickens A; Force SD; Steuer CE; Owonikoko TK; Ramalingam SS; Higgins K
Long-Term Survival in Stage IV Esophageal Adenocarcinoma with Chemoradiation and Serial Endoscopic Cryoablation.
Clin Endosc Volume: 50 Page(s): 491 - 494
09/01/2017 Authors: Spiritos Z; Mekaroonkamol P; El-Rayes BF; Force SD; Keilin SA; Cai Q; Willingham FF
Appendiceal Mucinous Neoplasms: Diagnosis and Management.
Oncologist Volume: 22 Page(s): 1107 - 1116
09/01/2017 Authors: Shaib WL; Assi R; Shamseddine A; Alese OB; Staley C; Memis B; Adsay V; Bekaii-Saab T; El-Rayes BF
Epigenetic effects of inhibition of heat shock protein 90 (HSP90) in human pancreatic and colon cancer.
Cancer Lett Volume: 402 Page(s): 110 - 116
08/28/2017 Authors: Nagaraju GP; Wu C; Merchant N; Chen Z; Lesinski GB; El-Rayes BF
LBA-002A phase 1b/II study of cancer stemness inhibitor napabucasin in combination with gemcitabine (gem) & nab-paclitaxel (nabptx) in metastatic pancreatic adenocarcinoma (mpdac) patients (pts).
Ann Oncol Volume: 28
06/01/2017 Authors: Bekaii-Saab T; Starodub A; El-Rayes B; O'Neil B; Shahda S; Ciombor K; Noonan A; Hanna W; Sehdev A; Shaib W
A phase 1b/II study of cancer stemness inhibitor napabucasin in combination with gemcitabine (gem) & nab-paclitaxel (nabptx) in metastatic pancreatic adenocarcinoma (mpdac) patients (pts).
Volume: 28 Suppl 3 Page(s): iii150
06/01/2017 Authors: Bekaii-Saab T; Starodub A; El-Rayes B; O'Neil B; Shahda S; Ciombor K; Noonan A; Hanna W; Sehdev A; Shaib W
ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 genetic aberrations.
Volume: 35
05/20/2017 Authors: Mazzaferro V; El-Rayes BF; Cotsoglou C; Harris WP; Damjanov N; Masi G; Rimassa L; Personeni N; Braiteh FS; Zagonel V
Safety and pharmacokinetics of crizotinib in patients (pts) with hepatic impairment (HI) and advanced cancer.
Volume: 35
05/20/2017 Authors: EI-Khoueiry AB; Sarantopoulos J; O'Bryant CL; Ciombor KK; Xu H; O'Gorman MT; Chakrabarti J; Usari T; El-Rayes BF
Safety of trifluridine/tipiracil for metastatic colorectal cancer in African American patients participating in an expanded access program.
Volume: 35
05/20/2017 Authors: Philip PA; Smaglo BG; El-Rayes BF; Lesuisse C; Makris L
A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer.
Volume: 35
05/20/2017 Authors: Shanda S; Noonan AM; Bekaii-Saab TS; O'Neil BH; Sehdev A; Shaib WL; Helft PR; Loehrer PJ; Tong Y; Liu Z
Chemotherapy with or without definitive radiation therapy in locally advanced pancreatic cancer.
Volume: 35
05/20/2017 Authors: Zhong J; Switchenko JM; Behera M; Kooby DA; McDonald MW; El-Rayes BF; Landry JC; Patel PR
Enrollment into molecular selection trials and impact on patient disposition.
Volume: 35
05/20/2017 Authors: Harvey RD; Steuer CE; Judson EC; Lewis CM; Collins HH; Saba NF; El-Rayes BF; Curran WJ; Rannalingam SS; Pentz RD
Phase IB study of induction chemotherapy with XELOX, followed by radiation therapy, carboplatin, and everolimus in patients with locally advanced esophageal cancer (EC).
Volume: 35
05/20/2017 Authors: Saba NF; Force SD; Staley CA; Fernandez FG; Willingham FF; Allan P; Cardona K; Chen Z; Cardin DB; Lambright E
Treatment, outcomes, and impact of racial disparities on young adults with pancreatic cancer.
Volume: 35
05/20/2017 Authors: Alese OB; Jiang R; Shaib WL; Wu CS-Y; Behera M; El-Rayes BF
Racial disparities in treatment and outcomes of colorectal cancer in young adults.
Volume: 35
05/20/2017 Authors: Alese OB; Jiang R; Shaib WL; Wu CS-Y; Behera M; El-Rayes BF
Identifying and targeting cancer stem cells in the treatment of gastric cancer.
Cancer Volume: 123 Page(s): 1303 - 1312
04/15/2017 Authors: Bekaii-Saab T; El-Rayes B
Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205).
J Clin Oncol Volume: 35 Page(s): 718 - 726
03/01/2017 Authors: Garg MK; Zhao F; Sparano JA; Palefsky J; Whittington R; Mitchell EP; Mulcahy MF; Armstrong KI; Nabbout NH; Kalnicki S
Current status of biomarker and targeted nanoparticle development: The precision oncology approach for pancreatic cancer therapy.
Cancer Lett Volume: 388 Page(s): 139 - 148
03/01/2017 Authors: Zhu L; Staley C; Kooby D; El-Rays B; Mao H; Yang L
Adenocarcinoma Ex-Goblet Cell Carcinoid of the Appendix Is a Tumor of Intestinal Lineage and Mucinous Differentiation
Volume: 30 Page(s): 196A - 196A
02/01/2017 Authors: Robinson B; Memis B; Toussaint A; Xue Y; Krasinskas A; Staley C; Winer JH; Russell MC; Shaib W; El-Rayes B
Adenocarcinoma Ex-Goblet Cell Carcinoid of the Appendix Is a Tumor of Intestinal Lineage and Mucinous Differentiation
Volume: 97 Page(s): 196A - 196A
02/01/2017 Authors: Robinson B; Memis B; Toussaint A; Xue Y; Krasinskas A; Staley C; Wino JH; Russell MC; Shaib W; El-Rayes B
HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for novel therapeutic targets.
Volume: 35
02/01/2017 Authors: Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K
HSP90 Expression and Early Recurrence in Gastroenteropancreatic Neuroendocrine Tumors: Potential for Novel Therapeutic Targets
Volume: 24 Page(s): S97 - S97
02/01/2017 Authors: Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes B; Russell M; Kooby D; Staley CA; Cardona K
Non-ampullary-duodenal carcinomas: clinicopathologic analysis of 47 cases and comparison with ampullary and pancreatic adenocarcinomas.
Mod Pathol Volume: 30 Page(s): 255 - 266
02/01/2017 Authors: Xue Y; Vanoli A; Balci S; Reid MM; Saka B; Bagci P; Memis B; Choi H; Ohike N; Tajiri T
Establishment of human metastatic colorectal cancer model in rabbit liver: A pilot study.
PLoS One Volume: 12 Page(s): e0177212
01/01/2017 Authors: Prieto V; Ludwig JM; Farris AB; Nagaraju GP; Lawal TO; El-Rayes B; Kim HS
Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.
Cancer Volume: 123 Page(s): 345 - 356
01/01/2017 Authors: Ma WW; Saif MW; El-Rayes BF; Fakih MG; Cartwright TH; Posey JA; King TR; von Borstel RW; Bamat MK
Adenosquamous Carcinoma of the Esophagus: An NCDB-Based Investigation on Comparative Features and Overall Survival in a Rare Tumor.
Oncology Volume: 93 Page(s): 336 - 342
01/01/2017 Authors: Evans M; Liu Y; Chen C; Steuer C; Cassidy R; Landry J; Higgins K; Beitler JJ; Willingham F; Owonikoko TK
Novel synthetic curcumin analogs as potent antiangiogenic agents in colorectal cancer.
Mol Carcinog Volume: 56 Page(s): 288 - 299
01/01/2017 Authors: Rajitha B; Nagaraju GP; Shaib WL; Alese OB; Snyder JP; Shoji M; Pattnaik S; Alam A; El-Rayes BF
An update on the multimodality of localized rectal cancer.
Crit Rev Oncol Hematol Volume: 108 Page(s): 23 - 32
12/01/2016 Authors: Artac M; Korkmaz L; El-Rayes B; Philip PA
Phase 1 Study of CEP-37250/KHK2804, a Tumor-specific Anti-glycoconjugate Monoclonal Antibody, in Patients with Advanced Solid Tumors.
Target Oncol Volume: 11 Page(s): 807 - 814
12/01/2016 Authors: Mita MM; Nemunaitis J; Grilley-Olson J; El-Rayes B; Bekaii-Saab T; Harvey RD; Marshall J; Zhang X; Strout V
Ampullary carcinoma is often of mixed or hybrid histologic type: an analysis of reproducibility and clinical relevance of classification as pancreatobiliary versus intestinal in 232 cases.
Mod Pathol Volume: 29 Page(s): 1575 - 1585
12/01/2016 Authors: Reid MD; Balci S; Ohike N; Xue Y; Kim GE; Tajiri T; Memis B; Coban I; Dolgun A; Krasinskas AM
Radiation Therapy Compliance/Quality Assurance (QA) in 2 Phase 2 Trials of Cetuximab Plus Combined Modality Therapy (CMT) Including Chemotherapy and Radiation Therapy (RT) for Patients With Squamous Cell Carcinoma of the Anal Canal (SCCAC) (AMC045)
Volume: 96 Page(s): S106 - S107
10/01/2016 Authors: Garg MK; Zhao F; Lee J; Sparano J; Palefsky J; Henry D; Wachsman W; Rajdev L; Aboulafia D; Mitchell E
Long-term Survival in Stage IV Esophageal Adenocarcinoma with Chemoradiation and Serial Endoscopic Cryoablation
Volume: 111 Page(s): S753 - S754
10/01/2016 Authors: Spiritos Z; Mekaroonkamol P; Willingham F; El-Rayes B; Force S; Keilin S; Cai Q
Radiation Therapy Compliance/Quality Assurance (QA) in 2 Phase 2 Trials of Cetuximab Plus Combined Modality Therapy (CMT) Including Chemotherapy and Radiation Therapy (RT) for Patients With Squamous Cell Carcinoma of the Anal Canal (SCCAC) (AMC045)
Volume: 96 Page(s): S106 - S107
10/01/2016 Authors: Garg MK; Zhao F; Lee J; Sparano J; Palefsky J; Henry D; Wachsman W; Rajdev L; Aboulafia D; Mitchell E
Adenocarcinoma ex-goblet cell carcinoid (appendiceal-type crypt cell adenocarcinoma) is a morphologically distinct entity with highly aggressive behavior and frequent association with peritoneal/intra-abdominal dissemination: an analysis of 77 cases.
Mod Pathol Volume: 29 Page(s): 1243 - 1253
10/01/2016 Authors: Reid MD; Basturk O; Shaib WL; Xue Y; Balci S; Choi H-J; Akkas G; Memis B; Robinson BS; El-Rayes BF
A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458).
Int J Radiat Oncol Biol Phys Volume: 96 Page(s): 296 - 303
10/01/2016 Authors: Shaib WL; Hawk N; Cassidy RJ; Chen Z; Zhang C; Brutcher E; Kooby D; Maithel SK; Sarmiento JM; Landry J
Prolonged survival in hepatocarcinoma patients with increased regucalcin gene expression: HepG2 cell proliferation is suppressed by overexpression of regucalcin in vitro.
Int J Oncol Volume: 49 Page(s): 1686 - 1694
10/01/2016 Authors: Yamaguchi M; Osuka S; Weitzmann MN; El-Rayes BF; Shoji M; Murata T
Radiation Therapy Compliance/Quality Assurance (QA) in 2 Phase 2 Trials of Cetuximab Plus Combined Modality Therapy (CMT) Including Chemotherapy and Radiation Therapy (RT) for Patients With Squamous Cell Carcinoma of the Anal Canal (SCCAC) (AMC045).
Int J Radiat Oncol Biol Phys Volume: 96 Page(s): S106 - S107
10/01/2016 Authors: Garg MK; Zhao F; Lee J; Sparano J; Palefsky J; Henry D; Wachsman W; Rajdev L; Aboulafia D; Mitchell E
Taking aim at the genomic diversity of gastrointestinal cancers: a changing landscape.
J Gastrointest Oncol Volume: 7 Page(s): 673 - 674
10/01/2016 Authors: Bekaii-Saab T; El-Rayes B
Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial.
J Surg Oncol Volume: 114 Page(s): 336 - 341
09/01/2016 Authors: Postlewait LM; Ethun CG; Kooby DA; Sarmiento JM; Chen Z; Staley CA; Brutcher E; Adsay V; El-Rayes B; Maithel SK
Concurrent inhibition of NF-kappa B, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer (Retraction of vol 110, pg 171, 2010)
JOURNAL OF CELLULAR BIOCHEMISTRY Volume: 117 Page(s): 1961 - 1961
08/01/2016 Authors: Ali S; Banerjee S; Schaffert JM; El-Rayes BF; Philip PA; Sarkar FH
Treatment allocation in patients with early-stage esophageal adenocarcinoma: Prevalence and predictors of lymph node involvement.
Cancer Volume: 122 Page(s): 2150 - 2157
07/15/2016 Authors: Gamboa AM; Kim S; Force SD; Staley CA; Woods KE; Kooby DA; Maithel SK; Luke JA; Shaffer KM; Dacha S
Tolfenamic acid and curcumin treatment induces pancreatic cancer cell growth inhibition via suppressing Sp1 expression, NF-kB translocation to nucleus
Volume: 76
07/01/2016 Authors: Basha RM; Connelly SF; Purnachandra G; Sankpal UT; Patel H; Vishwanatha JK; Shelake S; Tabor-Simeckal L; Shoji M; Simecka JSW
Combination of HSP90 and proteasome inhibitor is effective in pancreatic cancer
Volume: 76
07/01/2016 Authors: Nagaraju GP; Rajitha B; Benton L; El-Rayes BF
Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Edition) Inapplicable and Insignificant: A Size-Based Staging System(pT1: 2, pT2: >2-4, pT3: >4 cm) is More Valid and Clinically Relevant.
Ann Surg Oncol Volume: 23 Page(s): 2010 - 2018
06/01/2016 Authors: Saka B; Balci S; Basturk O; Bagci P; Postlewait LM; Maithel S; Knight J; El-Rayes B; Kooby D; Sarmiento J
Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma.
Mol Ther Volume: 24 Page(s): 1150 - 1158
06/01/2016 Authors: Noonan AM; Farren MR; Geyer SM; Huang Y; Tahiri S; Ahn D; Mikhail S; Ciombor KK; Pant S; Aparo S
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
Lancet Oncol Volume: 17 Page(s): 801 - 810
06/01/2016 Authors: Suker M; Beumer BR; Sadot E; Marthey L; Faris JE; Mellon EA; El-Rayes BF; Wang-Gillam A; Lacy J; Hosein PJ
ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA)
Volume: 27 Page(s): 109 - 109
06/01/2016 Authors: Mazzaferro V; Shaib W; Rimassa L; Harris W; Personeni N; El-Rayes B; Tolcher A; Hall T; Wang Y; Schwartz B
Phase 1b extension study of cancer stemness inhibitor BB608 (napabucasin) administered in combination with FOLFIRI plus /-bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC).
Volume: 34
05/20/2016 Authors: O'Neil BH; Hubbard JM; Starodub A; Jonker DJ; Edenfield WJ; El-Rayes BF; Halfdanarson TR; Ramanathan RK; Pitot HC; Britten CD
Uridine triacetate as a lifesaving antidote for overdoses and severe early-onset 5-fluorouracil and capecitabine toxicities.
Volume: 34
05/20/2016 Authors: Ma WW; Saif WM; Cartwright TH; Fakih M; El-Rayes BF; King T; Vanas J; von Borstel R; Bamat MK; Posey J
Uridine triacetate for early onset, severe life-threatening toxicities of 5-fluorouracil and capecitabine.
Volume: 34
05/20/2016 Authors: Cartwright TH; Ma WW; Fakih M; El-Rayes BF; Posey J; King T; Vanas J; von Borstel R; Bamat MK
Uridine triacetate as a life-saving antidote to capecitabine toxicity.
Volume: 34
05/20/2016 Authors: Ma WW; Cartwright TH; El-Rayes BF; Posey J; Fakih M; King T; von Borstel R; Bamat MK
Comparative features and overall survival in adenosquamous carcinoma, a rare tumor of the esophagus.
Volume: 34
05/20/2016 Authors: Evans M; Liu Y; Chen C; Gillespie TW; Steuer CE; Owonikoko TK; Ramalingam SS; Beitler JJ; El-Rayes BF; Fernandez F
Effect of definitive concurrent therapy with or without surgery on resectable esophageal cancer survival: An analysis of the National Cancer Data Base
Volume: 34
05/20/2016 Authors: Naik K; Liu Y; Goodman M; Gillespie TW; El-Rayes BF; Pickens A; Force S; Steuer CE; Owonikoko TK; Ramalingam SS
Prolonged survival in pancreatic cancer patients with increased regucalcin gene expression: Overexpression of regucalcin suppresses the proliferation in human pancreatic cancer MIA PaCa-2 cells in vitro.
Int J Oncol Volume: 48 Page(s): 1955 - 1964
05/01/2016 Authors: Yamaguchi M; Osuka S; Weitzmann MN; El-Rayes BF; Shoji M; Murata T
Small molecule tolfenamic acid and dietary spice curcumin treatment enhances antiproliferative effect in pancreatic cancer cells via suppressing Sp1, disrupting NF-kB translocation to nucleus and cell cycle phase distribution.
J Nutr Biochem Volume: 31 Page(s): 77 - 87
05/01/2016 Authors: Basha R; Connelly SF; Sankpal UT; Nagaraju GP; Patel H; Vishwanatha JK; Shelake S; Tabor-Simecka L; Shoji M; Simecka JW
Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer.
Med Oncol Volume: 33 Page(s): 48
05/01/2016 Authors: Goldstein DA; Krishna K; Flowers CR; El-Rayes BF; Bekaii-Saab T; Noonan AM
Inhibition of NF-B translocation by curcumin analogs induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer.
Cancer Lett Volume: 373 Page(s): 227 - 233
04/10/2016 Authors: Rajitha B; Belalcazar A; Nagaraju GP; Shaib WL; Snyder JP; Shoji M; Pattnaik S; Alam A; El-Rayes BF
Appendiceal Neuroendocrine, Goblet and Signet-Ring Cell Tumors: A Spectrum of Diseases with Different Patterns of Presentation and Outcome.
Cancer Res Treat Volume: 48 Page(s): 596 - 604
04/01/2016 Authors: Shaib W; Krishna K; Kim S; Goodman M; Rock J; Chen Z; Brutcher E; Staley CI; Maithel SK; Abdel-Missih S
Aquaporins: Their role in gastrointestinal malignancies.
Cancer Lett Volume: 373 Page(s): 12 - 18
04/01/2016 Authors: Nagaraju GP; Basha R; Rajitha B; Alese OB; Alam A; Pattnaik S; El-Rayes B
Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies.
J Mol Diagn Volume: 18 Page(s): 299 - 315
03/01/2016 Authors: Fisher KE; Zhang L; Wang J; Smith GH; Newman S; Schneider TM; Pillai RN; Kudchadkar RR; Owonikoko TK; Ramalingam SS
Phase Ib trial of gemcitabine with yttrium-90 in patients with hepatic tumors of pancreatobiliary origin.
Volume: 34
02/01/2016 Authors: Kim HS; Camacho JC; El-Rayes BF
A molecular biomarker targeted approach to adjuvant therapy for resected pancreatic adenocarcinoma: Results of a phase II prospective trial.
Volume: 34
02/01/2016 Authors: Postlewait LM; Ethun CG; Kooby DA; Sarmiento J; Staley CA; Brutcher E; Adsay V; El-Rayes BF; Maithel SK
A phase Ib study of cancer stem cell (CSC) pathway inhibitor BBI-608 in combination with gemcitabine and nab-paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).
Volume: 34
02/01/2016 Authors: Shahda S; El-Rayes BF; O'Neil BH; Starodub A; Hanna WT; Borodyansky L; Oh C; Li C; Bekaii-Saab TS
Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer.
Oncologist Volume: 21 Page(s): 178 - 187
02/01/2016 Authors: Shaib WL; Ip A; Cardona K; Alese OB; Maithel SK; Kooby D; Landry J; El-Rayes BF
A Molecular Biomarker Targeted Approach to Adjuvant Therapy for Resected Pancreatic Adenocarcinoma: Results of a Phase II Prospective Trial
Volume: 23 Page(s): S24 - S24
02/01/2016 Authors: Postlewait LM; Ethun CG; Kooby DA; Sarmiento JM; Staley CA; Brutcher E; Adsay V; El-Rayes B; Maithel SK
Adenocarcinoma Ex-Goblet Cell Carcinoid (XGC) Is a Morphologically Distinct "Appendiceal-Type Crypt Cell" Adenocarcinoma with Highly Aggressive Behavior and Frequent Association with Peritoneal/Intra-Abdominal Dissemination: An Analysis of 77 Cases
Volume: 96 Page(s): 194A - 194A
02/01/2016 Authors: Reid M; Basturk O; Shaib W; Balci S; Choi H; Akkas G; Robinson B; Memis B; El-Rayes B; Staley C
Significant Prognostic Factors in Invasive Ampullary Adenocarcinoma (AC): Clinicopathologic Analysis of 367 Cases
Volume: 29 Page(s): 194A - 194A
02/01/2016 Authors: Reid M; Balci S; Xue Y; Ohike N; Tajiri T; Basturk O; Muraki T; Kim GE; Krasinskas AM; Quigley B
Adenocarcinoma Ex-Goblet Cell Carcinoid (XGC) Is a Morphologically Distinct "Appendiceal-Type Crypt Cell" Adenocarcinoma with Highly Aggressive Behavior and Frequent Association with Peritoneal/Intra-Abdominal Dissemination: An Analysis of 77 Cases
Volume: 29 Page(s): 194A - 194A
02/01/2016 Authors: Reid M; Basturk O; Shaib W; Balci S; Choi H; Akkas G; Robinson B; Memis B; El-Rayes B; Staley C
Clinical trial experience with uridine triacetate for 5-fluorouracil toxicity.
Volume: 34
02/01/2016 Authors: Ma WW; Saif WM; El-Rayes BF; Fakih M; Cartwright TH; Posey J; von Borstel R; Bamat MK
Significant Prognostic Factors in Invasive Ampullary Adenocarcinoma (AC): Clinicopathologic Analysis of 367 Cases
Volume: 96 Page(s): 194A - 194A
02/01/2016 Authors: Reid M; Balci S; Xue Y; Ohike N; Tajiri T; Basturk O; Muraki T; Kim GE; Krasinskas AM; Quigley B
Combination of tolfenamic acid and curcumin induces colon cancer cell growth inhibition through modulating specific transcription factors and reactive oxygen species.
Oncotarget Volume: 7 Page(s): 3186 - 3200
01/19/2016 Authors: Sankpal UT; Nagaraju GP; Gottipolu SR; Hurtado M; Jordan CG; Simecka JW; Shoji M; El-Rayes B; Basha R
Adjuvant therapy for pancreas cancer in an era of value based cancer care.
Cancer Treat Rev Volume: 42 Page(s): 10 - 17
01/01/2016 Authors: Ahn DH; Williams TM; Goldstein DA; El-Rayes B; Bekaii-Saab T
MicroRNAs as biomarkers and prospective therapeutic targets in colon and pancreatic cancers.
Tumour Biol Volume: 37 Page(s): 97 - 104
01/01/2016 Authors: Nagaraju GP; Madanraj AS; Aliya S; Rajitha B; Alese OB; Kariali E; Alam A; El-Rayes BF
Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
Eur J Cancer Volume: 52 Page(s): 109 - 119
01/01/2016 Authors: Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
Broad targeting of angiogenesis for cancer prevention and therapy.
Semin Cancer Biol Volume: 35 Suppl Page(s): S224 - S243
12/01/2015 Authors: Wang Z; Dabrosin C; Yin X; Fuster MM; Arreola A; Rathmell WK; Generali D; Nagaraju GP; El-Rayes B; Ribatti D
Substaging Nodal Status in Ampullary Carcinomas has Significant Prognostic Value: Proposed Revised Staging Based on an Analysis of 313 Well-Characterized Cases.
Volume: 22 Page(s): 4392 - 4401
12/01/2015 Authors: Balci S; Basturk O; Saka B; Bagci P; Postlewait LM; Tajiri T; Jang K-T; Ohike N; Kim GE; Krasinskas A
Clinicopathologic Features and Outcome of Young Adults With Stage IV Colorectal Cancer.
Am J Clin Oncol Volume: 38 Page(s): 543 - 549
12/01/2015 Authors: Hawk NN; Long T-E; Imam MH; Mathew BM; Kim S; Chen Z; Goodman M; Sullivan P; Brutcher E; Kauh J
Analysis of liver-directed therapies in U.S. cancer patients.
Curr Oncol Volume: 22 Page(s): e457 - e461
12/01/2015 Authors: Alese OB; Kim S; Chen Z; Ramalingam SS; Owonikoko TK; El-Rayes BF
Designing a broad-spectrum integrative approach for cancer prevention and treatment.
Semin Cancer Biol Volume: 35 Suppl Page(s): S276 - S304
12/01/2015 Authors: Block KI; Gyllenhaal C; Lowe L; Amedei A; Amin ARMR; Amin A; Aquilano K; Arbiser J; Arreola A; Arzumanyan A
Substaging of Lymph Node Status in Resected Pancreatic Ductal Adenocarcinoma Has Strong Prognostic Correlations: Proposal for a Revised N Classification for TNM Staging.
Ann Surg Oncol Volume: 22 Suppl 3 Page(s): S1187 - S1195
12/01/2015 Authors: Basturk O; Saka B; Balci S; Postlewait LM; Knight J; Goodman M; Kooby D; Sarmiento JM; El-Rayes B; Choi H
The flavonoid p-hydroxycinnamic acid exhibits anticancer effects in human pancreatic cancer MIA PaCa-2 cells in vitro: Comparison with gemcitabine.
Oncol Rep Volume: 34 Page(s): 3304 - 3310
12/01/2015 Authors: Yamaguchi M; Murata T; El-Rayes BF; Shoji M
Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer.
Volume: 33 Page(s): 3727 - 3732
11/10/2015 Authors: Goldstein DA; Ahmad BB; Chen Q; Ayer T; Howard DH; Lipscomb J; El-Rayes BF; Flowers CR
Reply to A. Messori et al, R. Bordonaro et al, and G. Fasola et al.
J Clin Oncol Volume: 33 Page(s): 3842 - 3843
11/10/2015 Authors: Goldstein DA; El-Rayes BF; Chen Q; Flowers CR
Biomarkers for personalized medicine in GI cancers.
Mol Aspects Med Volume: 45 Page(s): 14 - 27
11/01/2015 Authors: Zhang SY; Zhang SQ; Nagaraju GP; El-Rayes BF
Heat shock protein 90 promotes epithelial to mesenchymal transition, invasion, and migration in colorectal cancer.
Mol Carcinog Volume: 54 Page(s): 1147 - 1158
10/01/2015 Authors: Nagaraju GP; Long T-E; Park W; Landry JC; Taliaferro-Smith L; Farris AB; Diaz R; El-Rayes BF
Hypoxia inducible factor-1: Its role in colorectal carcinogenesis and metastasis.
Cancer Lett Volume: 366 Page(s): 11 - 18
09/28/2015 Authors: Nagaraju GP; Bramhachari PV; Raghu G; El-Rayes BF
Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?
Oncologist Volume: 20 Page(s): 981 - 982
09/01/2015 Authors: Goldstein DA; El-Rayes BF
Inhibition of NF-kappa B translocation induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer
Volume: 75
08/01/2015 Authors: Nagaraju GP; Olatunji A; Gupta S; Shoji M; El-Rayes BF
A phase I pharmacokinetic and pharmacodynamic evaluation of the combination of everolimus and buparlisib for concurrent mTOR and PI3K pathway blockade in patients with advanced solid tumors
Volume: 75
08/01/2015 Authors: Owonikoko TK; Harvey RD; Lewis C; Chen Z; Kauh JS; Renfroe M; Deovic R; Sica GL; Carthon BC; Harris WB
Targeting NF-kappa B by the curcumin and its analogs EF-31 and UBS-109 decreases growth and angiogenesis of colon cancer
Volume: 75
08/01/2015 Authors: Nagaraju GP; Shoji M; El Rayes B
PIK3CA/BRAF mutations negatively affect outcome of patients with KRAS wild-type metastatic colorectal cancer treated with front line anti-EGFR monoclonal antibodies: Meta-analysis results
Volume: 75
08/01/2015 Authors: Mohamed A; Schrapp K; Attumi T; Saba NF; El-Rayes BF
Hyperthermic Intraperitoneal Chemotherapy Following Cytoreductive Surgery Improves Outcome in Patients With Primary Appendiceal Mucinous Adenocarcinoma: A Pooled Analysis From Three Tertiary Care Centers.
Oncologist Volume: 20 Page(s): 907 - 914
08/01/2015 Authors: Shaib WL; Martin LK; Choi M; Chen Z; Krishna K; Kim S; Brutcher E; Staley C; Maithel SK; Philip P
Combination of anti-cancer small molecule tolfenamic acid and curcumin effectively inhibits colon cancer cell growth
Volume: 75
08/01/2015 Authors: Sankpal UT; Nagaraju GP; Hurtado M; Gottipolu SR; El-Rayes B; Shoji M; Jordan CG; Basha R
Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach.
Volume: 22 Page(s): 2295 - 2301
07/01/2015 Authors: Squires MH; Volkan Adsay N; Schuster DM; Russell MC; Cardona K; Delman KA; Winer JH; Altinel D; Sarmiento JM; El-Rayes B
Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis.
Cancer Volume: 121 Page(s): 2164 - 2174
07/01/2015 Authors: Kokabi N; Camacho JC; Xing M; El-Rayes BF; Spivey JR; Knechtle SJ; Kim HS
Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
J Gastroenterol Hepatol Volume: 30 Page(s): 1167 - 1174
07/01/2015 Authors: Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
Management and Outcomes of Hospitalized Patients With Primary Neuroendocrine Tumor and Non-Neuroendocrine Tumor Appendiceal Cancers in the United States.
World J Oncol Volume: 6 Page(s): 349 - 354
06/01/2015 Authors: Alese OB; Kim S; Chen Z; Shaib W; Staley CA; Ramalingam SS; Owonikoko TK; El-Rayes BF
Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability.
J Surg Oncol Volume: 111 Page(s): 1028 - 1034
06/01/2015 Authors: Nanda RH; El-Rayes B; Maithel SK; Landry J
Radiotherapy patterns of care in gastric adenocarcinoma: a single institution experience.
J Gastrointest Oncol Volume: 6 Page(s): 247 - 253
06/01/2015 Authors: Cheng J; Squires MH; Mikell JL; Fisher SB; Staley CA; Kooby DA; El-Rayes BF; Curran WJ; Hall WA; Colbert LE
Management patterns and predictors of mortality among US patients with cancer hospitalized for malignant bowel obstruction.
Cancer Volume: 121 Page(s): 1772 - 1778
06/01/2015 Authors: Alese OB; Kim S; Chen Z; Owonikoko TK; El-Rayes BF
Phase I study of ganetespib (G), capecitabine (C), and radiation (RT) in rectal cancer
Volume: 33
05/20/2015 Authors: El-Rayes BF; Staley CA; Diaz R; Sullivan PS; Shaib WL; Landry JC
Pattern of liver-directed therapies and outcomes in cancer patients hospitalized in the United States
Volume: 33
05/20/2015 Authors: Alese OB; Kim S; Chen Z; Owonikoko TK; El-Rayes BF
Management and outcomes of hospitalized patients with primary neuroendocrine tumor (NET) and non-NET appendiceal cancers in the United States.
Volume: 33
05/20/2015 Authors: Alese OB; Kim S; Chen Z; Shaib WL; Owonikoko TK; El-Rayes BF
Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer
Volume: 33
05/20/2015 Authors: Goldstein DA; Ahmad BB; Chen Q; Ayer T; Howard DH; Lipscomb J; El-Rayes BF; Flowers C
Borderline resectable (BRPC) and locally advanced unresectable (LAPC) pancreas cancer treatment: A single Institution experience.
Volume: 33
05/20/2015 Authors: Shaib WL; Qu J; Zhang C; Ip A; Chen Z; El-Rayes BF; Alese O
Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibody.
J Drug Target Volume: 23 Page(s): 257 - 265
04/01/2015 Authors: Zhu S; Kisiel W; Lu YJ; Petersen LC; Ndungu JM; Moore TW; Parker ET; Sun A; Sarkaria JN; Snyder JP
First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis.
J Clin Oncol Volume: 33 Page(s): 1112 - 1118
04/01/2015 Authors: Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; El-Rayes BF; Flowers CR
Open pipelines for integrated tumor genome profiles reveal differences between pancreatic cancer tumors and cell lines.
Cancer Med Volume: 4 Page(s): 392 - 403
03/01/2015 Authors: Goecks J; El-Rayes BF; Maithel SK; Khoury HJ; Taylor J; Rossi MR
High nuclear hypoxia-inducible factor 1 alpha expression is a predictor of distant recurrence in patients with resected pancreatic adenocarcinoma.
Int J Radiat Oncol Biol Phys Volume: 91 Page(s): 631 - 639
03/01/2015 Authors: Colbert LE; Fisher SB; Balci S; Saka B; Chen Z; Kim S; El-Rayes BF; Adsay NV; Maithel SK; Landry JC
Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract.
Ther Adv Med Oncol Volume: 7 Page(s): 56 - 62
03/01/2015 Authors: Alese OB; El-Rayes BF; Sica G; Zhang G; Alexis D; La Rosa FG; Varella-Garcia M; Chen Z; Rossi MR; Adsay NV
Antiangiogenic effects of a novel synthetic curcumin analogue in pancreatic cancer.
Cancer Lett Volume: 357 Page(s): 557 - 565
02/28/2015 Authors: Nagaraju GP; Zhu S; Ko JE; Ashritha N; Kandimalla R; Snyder JP; Shoji M; El-Rayes BF
Comprehensive Genomic Profiling (CGP) of 122 Appendiceal Tumors Identifies Genomic Alterations (GA) Associated With Neuroendocrine and Signet Ring Differentiation
Volume: 95 Page(s): 158A - 159A
02/01/2015 Authors: Elvin J; Goldstein D; Wang K; Chalmers Z; Ali S; Chmielecki J; Stephens P; Lipson D; Yelensky R; Miller V
Comprehensive Genomic Profiling (CGP) of 122 Appendiceal Tumors Identifies Genomic Alterations (GA) Associated With Neuroendocrine and Signet Ring Differentiation
Volume: 28 Page(s): 158A - 159A
02/01/2015 Authors: Elvin J; Goldstein D; Wang K; Chalmers Z; Ali S; Chmielecki J; Stephens P; Lipson D; Yelensky R; Miller V
The anatomic location of pancreatic cancer as a prognostic factor for inpatient complications.
Volume: 33
01/20/2015 Authors: Zhang SY; Zhang SQ; Jiang JJ; El-Rayes BF
Prognostic value of gender in hospitalized pancreatic patients.
Volume: 33
01/20/2015 Authors: Zhang SY; Zhang SQ; Jiang JJ; El-Rayes BF
Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer (mPC).
Volume: 33
01/20/2015 Authors: Goldstein DA; Krishna K; Flowers C; El-Rayes BF; Bekaii-Saab TS; Noonan AM
Comprehensive genomic profiling of cancer of the appendix to reveal new routes to targeted therapies.
Volume: 33
01/20/2015 Authors: Goldstein DA; Elvin JA; Wang K; Shaib WL; Rossi MR; Stephens PJ; Ross JS; El-Rayes BF
Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
AJR Am J Roentgenol Volume: 203 Page(s): W706 - W714
12/01/2014 Authors: Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer.
Clin Colorectal Cancer Volume: 13 Page(s): 219 - 225
12/01/2014 Authors: Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; Harvey RD; El-Rayes BF; Flowers CR
Hepatoid adenocarcinoma of the lung: a case report and review of the literature.
J Gastrointest Cancer Volume: 45 Suppl 1 Page(s): 99 - 102
12/01/2014 Authors: Shaib W; Sharma R; Mosunjac M; Farris AB; El Rayes B
Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer.
Oncogene Volume: 33 Page(s): 5450 - 5456
11/20/2014 Authors: Hall WA; Petrova AV; Colbert LE; Hardy CW; Fisher SB; Saka B; Shelton JW; Warren MD; Pantazides BG; Gandhi K
Ethnic, gender, and age disparities and outcome of phase I clinical trials of biologically targeted anticancer agents
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION Volume: 23
11/01/2014 Authors: Owonikoko TK; Lewis C; Busari AK; Kim S; Chen Z; Lawson DH; Carthon BC; El-Rayes BF; Khuri FR; Kauh J
HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy.
Oncotarget Volume: 5 Page(s): 9980 - 9991
10/30/2014 Authors: Nagaraju GP; Alese OB; Landry J; Diaz R; El-Rayes BF
Combination of anti-cancer small molecule tolfenamic acid and curcumin or curcumin analog EF31 effectively inhibits pancreatic cancer cell growth
Volume: 74
10/01/2014 Authors: Basha R; Connelly SF; Nagaraju GP; Sankpal UT; Shoji M; Kayaleh O; El-Rayes B
Functional inhibition of HSP90 induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer
Volume: 74
10/01/2014 Authors: Nagaraju GP; Willingham FF; Woods KE; Sullivan P; Landry JC; Diaz R; El-Rayes BF
HSP90 as a therapeutic target in colorectal cancer
Volume: 74
10/01/2014 Authors: Nagaraju GP; Willingham FF; Woods KE; Sullivan P; Landry JC; Diaz R; El-Rayes BF
Nuclear Hypoxia-Inducible Factor 1 Alpha is a Predictor of Distant Failure in Patients With Resected Pancreatic Adenocarcinoma
Volume: 90 Page(s): S49 - S49
09/01/2014 Authors: Colbert L; Fisher SB; Balci S; Chen Z; Kim S; Adsay NV; Maithel SK; El-Rayes BF; Landry JC; Curran WJ
Value of intraoperative neck margin analysis during Whipple for pancreatic adenocarcinoma: a multicenter analysis of 1399 patients.
Ann Surg Volume: 260 Page(s): 494 - 501
09/01/2014 Authors: Kooby DA; Lad NL; Squires MH; Maithel SK; Sarmiento JM; Staley CA; Adsay NV; El-Rayes BF; Weber SM; Winslow ER
Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer.
Invest New Drugs Volume: 32 Page(s): 682 - 690
08/01/2014 Authors: Bendell JC; Lenz H-J; Ryan T; El-Rayes BF; Marshall JL; Modiano MR; Hart LL; Kingsley CD; George TJ; Nakashima D
Locoregional therapies for metastatic colorectal carcinoma to the liver--an evidence-based review.
J Surg Oncol Volume: 110 Page(s): 182 - 196
08/01/2014 Authors: Xing M; Kooby DA; El-Rayes BF; Kokabi N; Camacho JC; Kim HS
Targeted therapies in metastatic esophageal cancer: advances over the past decade.
Crit Rev Oncol Hematol Volume: 91 Page(s): 186 - 196
08/01/2014 Authors: Mohamed A; El-Rayes B; Khuri FR; Saba NF
Cost-effectiveness analysis of pharmacokinetic-guided (PK) 5-fluorouracil (5FU) when combined with leucovorin and oxaliplatin (FOLFOX) chemotherapy for metastatic colorectal cancer (mCRC)
Volume: 32
05/20/2014 Authors: Goldstein DA; Chen Q; Howard DH; Lipscomb J; Ayer T; Harvey D; El-Rayes BF; Flowers C
Cost-effectiveness analysis (CEA) of bevacizumab (Bev) in first- and second-line treatment of metastatic colorectal cancer (mCRC)
Volume: 32
05/20/2014 Authors: Goldstein DA; Chen Q; Howard DH; Lipscomb J; Ayer T; El-Rayes BF; Flowers C
Mortality from malignant bowel obstruction in hospitalized US cancer patients
Volume: 32
05/20/2014 Authors: Alese OB; Kim S; Chen Z; Owonikoko TK; El-Rayes BF
CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer.
Cancer Res Volume: 74 Page(s): 2677 - 2687
05/15/2014 Authors: Colbert LE; Petrova AV; Fisher SB; Pantazides BG; Madden MZ; Hardy CW; Warren MD; Pan Y; Nagaraju GP; Liu EA
Trends in the Incidence of Esophageal Adenocarcinoma and Early Stage Esophageal Adenocarcinoma in the United States
Volume: 146 Page(s): S566 - S567
05/01/2014 Authors: Gamboa AM; Kim S; Chen Z; Woods KE; Keilin S; Cai Q; Saba N; El-Rayes B; Willingham FF
Molecular mechanisms underlying the divergent roles of SPARC in human carcinogenesis.
Carcinogenesis Volume: 35 Page(s): 967 - 973
05/01/2014 Authors: Nagaraju GP; Dontula R; El-Rayes BF; Lakka SS
Treatment utilization and surgical outcome of ampullary and duodenal adenocarcinoma.
J Surg Oncol Volume: 109 Page(s): 556 - 560
05/01/2014 Authors: Shaib WL; Sharma R; Brutcher E; Kim S; Maithel SK; Chen Z; Kooby DA; Kauh J; Landry J; El-Rayes BF
Chemotherapeutic strategies in advanced or metastatic pancreatic adenocarcinoma.
Am J Clin Oncol Volume: 37 Page(s): 194 - 200
04/01/2014 Authors: Zafar SF; El-Rayes BF
Imaging and curcumin delivery in pancreatic cancer cell lines using PEGylated -Gd2(MoO4)3 mesoporous particles.
Dalton Trans Volume: 43 Page(s): 3330 - 3338
02/28/2014 Authors: Seeta Rama Raju G; Pavitra E; Nagaraju GP; Ramesh K; El-Rayes BF; Yu JS
Clinicopathologic Associations of Mismatch Repair Protein Expressions in Ampullary Carcinomas
Volume: 27 Page(s): 164A - 164A
02/01/2014 Authors: Balci S; Saka B; Krasinskas A; Kim G; Dursun N; Shaib W; El-Rayes B; Quigley B; Reid M; Farris AB
Clinicopathologic Associations of Mismatch Repair Protein Expressions in Ampullary Carcinomas
Volume: 94 Page(s): 164A - 164A
02/01/2014 Authors: Balci S; Saka B; Krasinskas A; Kim G; Dursun N; Shaib W; El-Rayes B; Quigley B; Reid M; Farris AB
Proposal for a Revised N-Stage for Pancreatic Ductal Adenocarcinoma as N1 (< 3) and N2 (>= 3) with Strong Prognostic Correlation
Volume: 27 Page(s): 448A - 448A
02/01/2014 Authors: Choi H; Saka B; Balci S; Basturk O; Maithel S; Kooby D; Sarmiento J; El-Rayes B; Knight J; Goodman M
HER2 in resected gastric cancer: Is there prognostic value?
J Surg Oncol Volume: 109 Page(s): 61 - 66
02/01/2014 Authors: Fisher SB; Fisher KE; Squires MH; Patel SH; Kooby DA; El-Rayes BF; Cardona K; Russell MC; Staley CA; Farris AB
Proposal for a New and Prognostically Valuable Tumor Size Based T-Stage for Pancreatic Adenocarcinoma
Volume: 94 Page(s): 453A - 453A
02/01/2014 Authors: Saka B; Balci S; Bagci P; Maithel S; Kooby D; Sarmiento J; Staley C; El-Rayes B; Choi H; Knight J
Abundance of IGG4-Positive Plasma Cells in Post-Neoadjuvant Ulcers of Gastroesophageal Carcinomas
Volume: 94 Page(s): 174A - 174A
02/01/2014 Authors: Genco I; Saka B; Balci S; Bradley K; Farris AB; Khosroshahi A; El-Rayes B; Krasinskas A; Staley C; Kooby D
Abundance of IGG4-Positive Plasma Cells in Post-Neoadjuvant Ulcers of Gastroesophageal Carcinomas
Volume: 27 Page(s): 174A - 174A
02/01/2014 Authors: Genco I; Saka B; Balci S; Bradley K; Farris AB; Khosroshahi A; El-Rayes B; Krasinskas A; Staley C; Kooby D
Will the pT1 and pT2 Pancreas Cancer Please Stand Up? "Peripancreatic Soft Tissue" Is Involved in Most Pancreatic Ductal Adenocarcinomas (PDAC), Negating Its Value as a Staging Parameter and Necessitating a New Staging Scheme
Volume: 27 Page(s): 454A - 454A
02/01/2014 Authors: Saka B; Oliva I; Bandyopadhyay S; Basturk O; Balci S; Maithel S; Kooby D; Sarmiento J; Staley C; El-Rayes B
Sub-Staging of Nodal Status in Ampullary Carcinomas as N1 (< 3) and N2(>= 3) Has Significant Prognostic Value: Proposal for Revised Staging Based on an Analysis of 313 Cases
Volume: 94 Page(s): 164A - 164A
02/01/2014 Authors: Bagci P; Balci S; Saka B; Hong S-M; Jang K-T; Ohike N; Kim G; Krasinskas A; Basturk O; Sarmiento J
Proposal for a Revised N-Stage for Pancreatic Ductal Adenocarcinoma as Ni (< 3) and N2
Volume: 94 Page(s): 448A - 448A
02/01/2014 Authors: Choi H; Saka B; Balci S; Basturk O; Maithel S; Kooby D; Sarmiento J; El-Rayes B; Knight J; Goodman M
Will the pT1 and pT2 Pancreas Cancer Please Stand Up? "Peripancreatic Soft Tissue" Is Involved in Most Pancreatic Ductal Adenocarcinomas (PDAC), Negating Its Value as a Staging Parameter and Necessitating a New Staging Scheme
Volume: 94 Page(s): 454A - 454A
02/01/2014 Authors: Saka B; Oliva I; Bandyopadhyay S; Basturk O; Balci S; Maithel S; Kooby D; Sarmiento J; Staley C; El-Rayes B
Proposal for a New and Prognostically Valuable Tumor Size Based T-Stage for Pancreatic Adenocarcinoma
Volume: 27 Page(s): 453A - 453A
02/01/2014 Authors: Saka B; Balci S; Bagci P; Maithel S; Kooby D; Sarmiento J; Staley C; El-Rayes B; Choi H; Knight J
Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.
J Vasc Interv Radiol Volume: 25 Page(s): 256 - 265
02/01/2014 Authors: Camacho JC; Kokabi N; Xing M; Prajapati HJ; El-Rayes B; Kim HS
Association of radiation therapy with overall survival in patients undergoing surgery for T3N0M0 adenocarcinoma of the rectum.
Volume: 32
01/20/2014 Authors: Marcus DM; Nickleach D; El-Rayes BF; Landry JC
Open-label prospective study of safety and efficacy of glass-based Y-90 radioembolization for infiltrative HCC with PVT
Volume: 32
01/20/2014 Authors: Kokabi N; Camacho JC; Xing M; Kauh JS; El-Rayes BF; Kim HS
Survival trends in unresectable hepatocellular carcinoma and the effect of DEB-TACE: SEER versus tertiary cancer center
Volume: 32
01/20/2014 Authors: Xing M; Prajapati HJ; Kokabi N; Camacho JC; El-Rayes BF; Kim HS
Survival trends in chemorefractory unresectable intrahepatic cholangiocarcinoma (ICC) and the effect of yttrium-90 (Y90) radioembolization: SEER versus tertiary cancer center
Volume: 32
01/20/2014 Authors: Xing M; Prajapati HJ; Kokabi N; Camacho JC; El-Rayes BF; Kim HS
Tumor angiogenesis therapy using targeted delivery of Paclitaxel to the vasculature of breast cancer metastases.
J Drug Deliv Volume: 2014 Page(s): 865732
01/01/2014 Authors: Zhu S; Kisiel W; Lu YJ; Petersen LC; Ndungu JM; Moore TW; Parker ET; Sun A; Liotta DC; El-Rayes BF
Novel synthetic curcumin analogues EF31 and UBS109 are potent DNA hypomethylating agents in pancreatic cancer.
Cancer Lett Volume: 341 Page(s): 195 - 203
12/01/2013 Authors: Nagaraju GP; Zhu S; Wen J; Farris AB; Adsay VN; Diaz R; Snyder JP; Mamoru S; El-Rayes BF
Incidence and prognosis of gastroesophageal cancer in rural, urban, and metropolitan areas of the United States.
Cancer Volume: 119 Page(s): 4020 - 4027
11/15/2013 Authors: Wang Z; Goodman M; Saba N; El-Rayes BF
Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma.
Pancreas Volume: 42 Page(s): 1311 - 1315
11/01/2013 Authors: Mahaseth H; Brutcher E; Kauh J; Hawk N; Kim S; Chen Z; Kooby DA; Maithel SK; Landry J; El-Rayes BF
Geographic differences in approach to advanced gastric cancer: Is there a standard approach?
Crit Rev Oncol Hematol Volume: 88 Page(s): 416 - 426
11/01/2013 Authors: Kim R; Tan A; Choi M; El-Rayes BF
Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1 and STAT-3.
Angiogenesis Volume: 16 Page(s): 903 - 917
10/01/2013 Authors: Nagaraju GP; Park W; Wen J; Mahaseth H; Landry J; Farris AB; Willingham F; Sullivan PS; Proia DA; El-Hariry I
Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma.
Cancer Volume: 119 Page(s): 3148 - 3155
09/01/2013 Authors: Colbert LE; Fisher SB; Hardy CW; Hall WA; Saka B; Shelton JW; Petrova AV; Warren MD; Pantazides BG; Gandhi K
Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma.
Cancer Volume: 119 Page(s): 3242 - 3250
09/01/2013 Authors: Squires MH; Fisher SB; Fisher KE; Patel SH; Kooby DA; El-Rayes BF; Staley CA; Farris AB; Maithel SK
Clinico-pathological characteristics of younger, middle aged, and older patients with colon cancer
Volume: 49 Page(s): S526 - S526
09/01/2013 Authors: Salem M; Kaufman M; Stanski N; Dyson G; Krasnick B; Choi M; Hawk N; El-Rayes B; Philip P
Markers of resistance to anti-EGFR therapy in colorectal cancer.
J Gastrointest Oncol Volume: 4 Page(s): 308 - 318
09/01/2013 Authors: Shaib W; Mahajan R; El-Rayes B
Pleiotropic effects of genistein in metabolic, inflammatory, and malignant diseases.
Nutr Rev Volume: 71 Page(s): 562 - 572
08/01/2013 Authors: Nagaraju GP; Zafar SF; El-Rayes BF
90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness.
J Comp Eff Res Volume: 2 Page(s): 435 - 444
07/01/2013 Authors: Xing M; Kokabi N; Camacho JC; Kooby DA; El-Rayes BF; Kim HS
In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells.
Int J Radiat Oncol Biol Phys Volume: 86 Page(s): 469 - 476
07/01/2013 Authors: Shelton JW; Waxweiler TV; Landry J; Gao H; Xu Y; Wang L; El-Rayes B; Shu H-KG
Risk factors for rising incidence of esophageal and gastric cardia adenocarcinoma.
J Gastrointest Cancer Volume: 44 Page(s): 143 - 151
06/01/2013 Authors: Carr JS; Zafar SF; Saba N; Khuri FR; El-Rayes BF
Survival outcome of ampullary and duodenal adenocarcinomas.
Volume: 31
05/20/2013 Authors: Shaib WL; Sharma R; Kim S; Chen Z; Kauh JS; Kooby DA; Maithel SK; Landry JC; El-Rayes BF
A retrospective cohort study of inpatient chemotherapy utilization in hospitalized advanced lung cancer patients in the United States.
Volume: 31
05/20/2013 Authors: Kang H; Kim S; Chen Z; El-Rayes BF; Brandes JC; Saba NF; Khuri FR; Ramalingam SS; Owonikoko TK
Multiplatform assessment of anaplastic lymphoma kinase (ALK) gene rearrangement in signet ring cell carcinoma of the gastrointestinal tract
Volume: 31
05/20/2013 Authors: Alese OB; El-Rayes BF; Sica G; Zhang G; Rossi MR; Adsay V; Alexis D; La Rosa FG; Varella-Garcia M; Chen Z
Doxorubicin drug eluting beads transcatheter chemoembolization (DEB TACE) in patients with large hepatocellular carcinoma (HCC): Overall survival and a multivariate analysis (MVA) of prognostic factors.
Volume: 31
05/20/2013 Authors: Prajapati HJ; Spivey JR; El-Rayes BF; Kauh JS; Kim HS
Early therapy response assessment by apparent diffusion coefficient (ADC) quantification following glass-based yttrium-90 radioembolization for unresectable hepatocellular carcinoma (HCC).
Volume: 31
05/20/2013 Authors: Kokabi N; Camacho JC; El-Rayes BF; Kauh JS; Kim HS
Heat shock protein 90 functional inhibition regulates epithelial to mesenchymal transformation, invasion and migration via NF-kB and HIF-1 alpha signaling in colorectal cancer
Volume: 73
04/15/2013 Authors: Ganji P; Long T-E; Mummareddi PM; Park W; Willingham FF; Landry JC; Sullivan P; Taliaferro-Smith L; Diaz R; El-Rayes B
A pilot clinical trial of chromodomain-helicase-DNA-binding protein 7 (CHD7) expression as a prognostic and predictive biomarker in patients with early-stage pancreatic adenocarcinoma.
Volume: 73
04/15/2013 Authors: Colbert LE; Hall WA; Hardy CW; Fisher SB; Yu DS; Maithel SK; El-Rayes B; Saka B; Adsay NV; Petrova A
mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).
Ann Oncol Volume: 24 Page(s): 965 - 973
04/01/2013 Authors: Prajapati HJ; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline.
J Clin Oncol Volume: 31 Page(s): 1357 - 1370
04/01/2013 Authors: Schiffer CA; Mangu PB; Wade JC; Camp-Sorrell D; Cope DG; El-Rayes BF; Gorman M; Ligibel J; Mansfield P; Levine M
Antiangiogenic activity of the HSP90 inhibitor ganetespib in pancreatic cancer models
Volume: 27
04/01/2013 Authors: Ganji PN; Diaz R; El-Rayes B
Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study.
Cardiovasc Intervent Radiol Volume: 36 Page(s): 440 - 448
04/01/2013 Authors: Rafi S; Piduru SM; El-Rayes B; Kauh JS; Kooby DA; Sarmiento JM; Kim HS
Anti-angiogenic effects of curcumin and its novel analogs EF-31 and UBS-109 in colorectal cancer
Volume: 27
04/01/2013 Authors: Ganji PN; Zhu S; Ko JE; Shoji M; El-Rayes B
A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies.
Br J Cancer Volume: 108 Page(s): 762 - 765
03/05/2013 Authors: Harvey RD; Owonikoko TK; Lewis CM; Akintayo A; Chen Z; Tighiouart M; Ramalingam SS; Fanucchi MP; Nadella P; Rogatko A
Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
J Vasc Interv Radiol Volume: 24 Page(s): 307 - 315
03/01/2013 Authors: Prajapati HJ; Dhanasekaran R; El-Rayes BF; Kauh JS; Maithel SK; Chen Z; Kim HS
Detailed Evaluation of the Lymph Nodes in N0 Cases with Additional Levels Ought To Be Considered for the Accurate Staging of Proximal Biliary Tract Cancers
Volume: 26 Page(s): 397A - 398A
02/01/2013 Authors: Bagci P; Maithel S; Fisher S; Saka B; Ocuin L; Patel S; Kooby D; Staley C; Sarmiento J; El-Rayes B
Neuroendocrine tumors (NET) of the gastrointestinal tract: Patterns of management and experience at Winship Cancer Institute of Emory University
Volume: 31
02/01/2013 Authors: Zafar SF; Patil DH; Kauh JS; Adsay V; Brutcher E; Maithel SK; Wang Z; Chen Z; El-Rayes BF
Clinicopathologic Comparison of Ampullary Versus Pancreatic Carcinoma: Preinvasive Component, Size of Invasion, Stage, Resectability and Histologic Phenotype Are the Factors for the Significantly Favorable Outcome of Ampullary Carcinoma
Volume: 26 Page(s): 429A - 429A
02/01/2013 Authors: Saka B; Tajiri T; Ohike N; Bagci P; Krasinskas A; Kim GE; Maithel SK; Sarmiento J; Kooby D; Ozdemir D
Clinicopathologic Comparison of Ampullary Versus Pancreatic Carcinoma: Preinvasive Component, Size of Invasion, Stage, Resectability and Histologic Phenotype Are the Factors for the Significantly Favorable Outcome of Ampullary Carcinoma
Volume: 93 Page(s): 429A - 429A
02/01/2013 Authors: Saka B; Tajiri T; Ohike N; Bagci P; Krasinskas A; Kim GE; Maithel SK; Sarmiento J; Kooby D; Ozdemir D
Differential Expression and Prognostic Value of ERCC1 and Thymidylate Synthase in Resected Gastric Adenocarcinoma
Volume: 20 Page(s): S138 - S138
02/01/2013 Authors: Squires MH; Fisher SB; Fisher KE; Patel SH; Kooby D; Staley CA; Farris AB; Maithel SK
Detailed Evaluation of the Lymph Nodes in N0 Cases with Additional Levels Ought To Be Considered for the Accurate Staging of Proximal Biliary Tract Cancers
Volume: 93 Page(s): 397A - 398A
02/01/2013 Authors: Bagci P; Maithel S; Fisher S; Saka B; Ocuin L; Patel S; Kooby D; Staley C; Sarmiento J; El-Rayes B
Neoplasms and Pseudotumors Associated with Low (Intrapancreatic) Union of Cystic Duct into Common Bile Duct: A Clinicopathologic Analysis of 15 Cases of a Hitherto Unrecognized Phenomenon
Volume: 93 Page(s): 424A - 424A
02/01/2013 Authors: Gonzalez RS; Saka B; Bagci P; Erbarut I; Maithel SK; Kooby D; Staley C; El-Rayes B; Sarmiento J; Everett R
Neoplasms and Pseudotumors Associated with Low (Intrapancreatic) Union of Cystic Duct into Common Bile Duct: A Clinicopathologic Analysis of 15 Cases of a Hitherto Unrecognized Phenomenon
Volume: 26 Page(s): 424A - 424A
02/01/2013 Authors: Gonzalez RS; Saka B; Bagci P; Erbaraut I; Maithel SK; Kooby D; Staley C; El-Rayes B; Sarmiento J; Everett R
An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment.
Cancer Volume: 119 Page(s): 445 - 453
01/15/2013 Authors: Fisher SB; Patel SH; Bagci P; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Maithel SK
Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.
Cancer Volume: 119 Page(s): 285 - 292
01/15/2013 Authors: Bauer TM; El-Rayes BF; Li X; Hammad N; Philip PA; Shields AF; Zalupski MM; Bekaii-Saab T
Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.
Cancer Volume: 119 Page(s): 454 - 462
01/15/2013 Authors: Fisher SB; Fisher KE; Patel SH; Lim MG; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Farris AB; Maithel SK
SPARC and DNA methylation: possible diagnostic and therapeutic implications in gastrointestinal cancers.
Cancer Lett Volume: 328 Page(s): 10 - 17
01/01/2013 Authors: Nagaraju GP; El-Rayes BF
Tools to optimize the functionality of a leukemia clinical trial team.
Leuk Lymphoma Volume: 54 Page(s): 110 - 116
01/01/2013 Authors: Bethelmie-Bryan B; Lord K; Holloway S; Safavi F; Shepard M; Rogers S; Harvey RD; Rodger K; Waller EK; El-Rayes B
A Loss of Function Genetic Screen Identifies Determinants of Sensitivity to PARP Inhibitor ABT-888 in Pancreatic Cancer
Volume: 84 Page(s): S325 - S325
11/01/2012 Authors: Park W; Pantazides BG; El-Rayes BF; Shelton JW; Yu DS
A Synthetic Lethal Screen Identifies Genes That Mediate Gemcitabine Resistance in Pancreatic Cancer
Volume: 84 Page(s): S88 - S88
11/01/2012 Authors: Pantazides B; Hardy C; Gandhi K; Landry J; Shelton J; Maithel S; El-Rayes B; Kowalski J; Yu D
Ganetespib, an HSP90 Inhibitor, Sensitizes Colorectal Cancers to the Effects of Ionizing Radiation
Volume: 84 Page(s): S696 - S697
11/01/2012 Authors: Diaz R; Nagaraju GP; Park W; El-Rayes BF; Landry JC
Salvage Yttrium-90 Radioembolization after Failed Chemotherapy for Colorectal Cancer Liver Metastases
Volume: 56 Page(s): 842A - 843A
10/01/2012 Authors: Lawal TO; Prajapati HJ; El-Rayes BF; Kauh JS; Kim HS
Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization.
J Vasc Interv Radiol Volume: 23 Page(s): 1286 - 93.e1
10/01/2012 Authors: Prajapati HJ; Rafi S; El-Rayes BF; Kauh JS; Kooby DA; Kim HS
The impact of curcumin on breast cancer.
Integr Biol (Camb) Volume: 4 Page(s): 996 - 1007
09/01/2012 Authors: Nagaraju GP; Aliya S; Zafar SF; Basha R; Diaz R; El-Rayes BF
Oxaliplatin-induced hepatoportal sclerosis, portal hypertension, and variceal bleeding successfully treated with transjugular intrahepatic portosystemic shunt.
Clin Colorectal Cancer Volume: 11 Page(s): 224 - 227
09/01/2012 Authors: Lawal TO; Farris AB; El-Rayes BF; Subramanian RM; Kim HS
Association between COX-2 expression and effectiveness of COX-2 inhibitors in a phase II trial in patients with metastatic colorectal adenocarcinoma.
Anticancer Res Volume: 32 Page(s): 3559 - 3563
08/01/2012 Authors: Almhanna K; El-Rayes B; Sethi S; Dyson G; Heilbrun L; Philip PA; Sarkar F
Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma.
Expert Opin Ther Targets Volume: 16 Page(s): 707 - 718
07/01/2012 Authors: Zafar SF; Nagaraju GP; El-Rayes B
Neuroendocrine tumors (NET) of the gastrointestinal tract: Experience at Winship Cancer Institute of Emory University
Volume: 30
05/20/2012 Authors: Zafar SF; Patil DH; Kauh JS; Adsay V; Kooby DA; Brutcher E; Maithel SK; El-Rayes BF
Safety and efficacy of modified FOLFIRINOX in pancreatic cancer: A retrospective experience
Volume: 30
05/20/2012 Authors: Mahaseth H; Kauh JS; Brutcher E; Hawk NN; Kim S; Chen Z; El-Rayes BF
Novel methods of analyzing long-term trends in incidence and survival applied to gastroesophageal cancers
Volume: 30
05/20/2012 Authors: Wang Z; Goodman M; Mahaseth H; El-Rayes BF
A phase I study of the safety and pharmacodynamic effects of everolimus in combination with lenalidomide in patients with advanced solid malignancies.
Volume: 30
05/20/2012 Authors: Owonikoko TK; Harvey RD; Kauh JS; Lewis CM; Hossain MS; Akintayo AO; Merriewether AR; Chen Z; Hawk NN; Saba NF
A phase I and pharmacokinetic study of multiple schedules of ganetespib (STA-9090), a heat shock protein 90 inhibitor, in combination with docetaxel for subjects with advanced solid tumor malignancies
Volume: 30
05/20/2012 Authors: Kauh JS; Harvey RD; Owonikoko TK; El-Rayes BF; Shin DM; Murali S; Lewis CM; Karol MD; Teofilovici F; Du Y
A comparative analysis of locoregional therapy (hyperthermic intraperitoneal chemotherapy [HIPEC]) and systemic chemotherapy (CT) following cytoreductive surgery in patients (pts) with disseminated mucinous appendiceal cancers (MACA).
Volume: 30
05/20/2012 Authors: Bekaii-Saab TS; Martin LK; Vallabhaneni GD; Park W; Staley CA; Maithel SK; Wang Z; Chen Z; El-Rayes BF
Survival outcomes of patients with unresectable hepatocellular carcinoma in a national population-based study: SEER versus tertiary cancer center
Volume: 30
05/20/2012 Authors: Lawal TO; El-Rayes BF; Kim HS
A synthetic lethal screen identifies genetic determinants for gemcitabine sensitivity in pancreatic cancer
CANCER RESEARCH Volume: 72
04/15/2012 Authors: Landry JC; Pantazides BG; Park W; Shelton JW; Maithel SK; El-Rayes B; Yu DS
Antiangiogenic effects associated with the inhibition of HSP90 in colorectal cancer
CANCER RESEARCH Volume: 72
04/15/2012 Authors: Mahaseth H; Nagaraju GP; Diaz R; Taliaferro-Smith LD; Landry JC; Saba NF; El-Rayes BF
Potent curcumin analogues inhibit pancreatic cancer cell growth and angiogenesis
CANCER RESEARCH Volume: 72
04/15/2012 Authors: Nagaraju GP; Zhu S; Diaz R; Shoji M; El-Rayes BF
Functional inhibition of HSP90 potentiates the effects of ionizing radiation in colorectal cancer
CANCER RESEARCH Volume: 72
04/15/2012 Authors: Nagaraju GP; Wen J; El-Rayes BF; Landry JC; Park W; Diaz R
An analysis of ERCC1, hENT1, RRM1, and RRM2 expression in resected pancreas adenocarcinoma: Implications for adjuvant treatment.
J Clin Oncol Volume: 30 Page(s): 206
02/01/2012 Authors: Fisher SB; Patel SH; Bagci P; Kooby DA; El-Rayes BF; Staley CA; Adsay V; Maithel SK
An Analysis of ERCC1, hENT1, RRM1, and RRM2 Expression in Intrahepatic vs Extrahepatic Biliary Tract Malignancy: Implications for Treatment?
Volume: 19 Page(s): S53 - S53
02/01/2012 Authors: Fisher SB; Fisher KE; Patel SH; El-Rayes BF; Staley CA; Kooby DA; Adsay N; Farris AB; Maithel SK
An analysis of ERCC1, hENT1, RRM1, and RRM2 expression in resected pancreas adenocarcinoma: Implications for adjuvant treatment.
Volume: 30
02/01/2012 Authors: Fisher SB; Patel SH; Bagci P; Kooby DA; El-Rayes BF; Staley CA; Adsay V; Maithel SK
Monoclonal Antibodies against Epidermal Growth Factor Receptor in Solid Tumors.
Chemother Res Pract Volume: 2012 Page(s): 291421
01/01/2012 Authors: Saba NF; Yom SS; Haigentz M; El-Rayes B
Clinically relevant biomarkers to select patients for targeted inhibitor therapy after resection of hepatocellular carcinoma.
Ann Surg Oncol Volume: 18 Page(s): 3384 - 3390
11/01/2011 Authors: Patel SH; Kneuertz PJ; Delgado M; Kooby DA; Staley CA; El-Rayes BF; Kauh JS; Sarmiento JM; Hanish S; Cohen C
MAGNETIC RESONANCE IMAGING PREDICTS SURVIVAL AFTER DOXORUBICIN DRUG ELUTING BEADS CHEMOEMBOLIZATION IN UNRESECTABLE HEPATOCELLULAR CARCINOMA
Volume: 54 Page(s): 900A - 901A
10/01/2011 Authors: Prajapati HJ; Spivey J; Hanish SI; Cherr Z; El-Rayes BF; Kauh JS; Kim HS
Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection.
Ann Surg Oncol Volume: 18 Page(s): 2699 - 2705
09/01/2011 Authors: Maithel SK; Coban I; Kneuertz PJ; Kooby DA; El-Rayes BF; Kauh JS; Sarmiento J; Staley CA; Volkan Adsay N
A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer.
Invest New Drugs Volume: 29 Page(s): 694 - 699
08/01/2011 Authors: El-Rayes BF; Philip PA; Sarkar FH; Shields AF; Ferris AM; Hess K; Kaseb AO; Javle MM; Varadhachary GR; Wolff RA
Bevacizumab (Bev) plus chemotherapy for advanced gastroesophageal adenocarcinoma (GC): Combined U. S. experience
JOURNAL OF CLINICAL ONCOLOGY Volume: 29
05/20/2011 Authors: Smyth EC; Enzinger PC; Li J; Vincitore M; Lacy J; El-Rayes BF; Kunz PL; Ford JM; Robinson E; Kelsen DP
Survival outcomes of nonoperative therapy (NOT) alone versus NOT followed by surgery (NOTS) in patients with esophageal cancer (EC): SEER analysis 2000-2007.
JOURNAL OF CLINICAL ONCOLOGY Volume: 29
05/20/2011 Authors: Saba NF; Kim HM; El-Rayes BF; Kono SA; Ramalingam SS; Owonikoko TK; Landry JC; Miller DL; Shin DM; Khuri FR
CA19-9 for the prediction of efficacy of chemotherapy in patients with advanced pancreas cancer: A pooled analysis of six prospective trials.
JOURNAL OF CLINICAL ONCOLOGY Volume: 29
05/20/2011 Authors: Bauer TM; Bekaii-Saab TS; Li X; Villalona-Calero MA; Philip PA; Shields AF; Zalupski MM; Hammad N; El-Rayes BF
Survival outcomes of nonoperative therapy (NOT) alone versus NOT followed by surgery (NOTS) in patients with esophageal cancer (EC): SEER analysis 2000-2007.
J Clin Oncol Volume: 29 Page(s): e14569
05/20/2011 Authors: Saba NF; Kim HM; El-Rayes BF; Kono SA; Ramalingam SS; Owonikoko TK; Landry JC; Miller DL; Shin DM; Khuri FR
Squamous cell cancer of the anal canal in HIV-infected patients receiving highly active antiretroviral therapy: a single institution experience.
Am J Clin Oncol Volume: 34 Page(s): 135 - 139
04/01/2011 Authors: Hammad N; Heilbrun LK; Gupta S; Tageja N; Philip PA; Shields AF; Smith D; El-Rayes BF
Clinicopathological analysis of primary epithelial appendiceal neoplasms.
Med Oncol Volume: 27 Page(s): 1073 - 1078
12/01/2010 Authors: Gupta S; Parsa V; Adsay V; Heilbrun LK; Smith D; Shields AF; Weaver D; Philip PA; El-Rayes BF
Impact of race, age, and socioeconomic status on participation in pancreatic cancer clinical trials.
Pancreas Volume: 39 Page(s): 967 - 971
10/01/2010 Authors: El-Rayes BF; Jasti P; Severson RK; Almhanna K; Philip PA; Shields A; Zalupski M; Heilbrun LK
A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers.
Ann Oncol Volume: 21 Page(s): 1999 - 2004
10/01/2010 Authors: El-Rayes BF; Zalupski M; Bekai-Saab T; Heilbrun LK; Hammad N; Patel B; Urba S; Shields AF; Vaishampayan U; Dawson S
MULTIVARIATE SURVIVAL ANALYSIS OF PREDICTIVE FACTORS OF HEPATOCELLULAR CARCINOMA TREATED WITH DOXORUBICIN DRUG ELUTING BEADS TRANSCATHETER CHEMOEMBOLIZATION
Volume: 52 Page(s): 1165A - 1166A
10/01/2010 Authors: Dhanasekaran R; Rafi S; El-Rayes BF; Kauh JS; Kooby DA; Kim HS
CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy.
Asia Pac J Clin Oncol Volume: 6 Page(s): 98 - 105
06/01/2010 Authors: Hammad N; Heilbrun LK; Philip PA; Shields AF; Zalupski MM; Venkatramanamoorthy R; El-Rayes BF
Chemoembolization with doxorubicin drug-eluting beads for unresectable hepatocelluar carcinoma with portal vein thrombosis
JOURNAL OF CLINICAL ONCOLOGY Volume: 28
05/20/2010 Authors: McIntosh EB; Dhanasekaran R; Kauh JS; El-Rayes BF; Kooby DA; Williams RS; Kim HS
Long-term survival after locoregional therapy in patients with unresectable hepatocellular carcinoma: Improvements over two decades.
JOURNAL OF CLINICAL ONCOLOGY Volume: 28
05/20/2010 Authors: Dhanasekaran R; McIntosh EB; Kauh JS; Kooby DA; El-Rayes BF; Kim HS
Phase IB dose escalation study of bortezomib and sunitinib in patients with refractory solid tumors.
JOURNAL OF CLINICAL ONCOLOGY Volume: 28
05/20/2010 Authors: Kauh JS; Harvey RD; Lawson DH; Owonikoko TK; Tighiouart M; Ramalingam SS; Shin DM; Lewis CM; El-Rayes BF; Khuri FR
Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer.
J Cell Biochem Volume: 110 Page(s): 171 - 181
05/01/2010 Authors: Ali S; Banerjee S; Schaffert JM; El-Rayes BF; Philip PA; Sarkar FH
Dedifferentiated Goblet Cell Carcinoid (Adenocarcinoma Ex GCC) Is a Morphologically Distinctive and Aggressive Neoplasm with Peritoneal Dissemination: An Analysis of 35 Cases
Volume: 90 Page(s): 137A - 137A
02/01/2010 Authors: Basturk O; Cheng J; Philip P; El-Rayes B; Coban I; Bandyopadhyay S; Cuhaci N; Adsay NV
Dedifferentiated Goblet Cell Carcinoid (Adenocarcinoma Ex GCC) Is a Morphologically Distinctive and Aggressive Neoplasm with Peritoneal Dissemination: An Analysis of 35 Cases
Volume: 23 Page(s): 137A - 137A
02/01/2010 Authors: Basturk O; Cheng J; Philip P; El-Rayes B; Coban I; Bandyopadhyay S; Cuhaci N; Adsay NV
Concurrent Inhibition of NF kappa B, Cyclooxygenase-2 and Epidermal Growth Factor Toward Pancreatic Cancer Therapy
PANCREAS Volume: 38 Page(s): 981 - 981
11/01/2009 Authors: Ali S; Banerjee S; Schaffert JM; El-Rayes BF; Philip PA; Sarkar FH
Protein kinases C isozymes are differentially expressed in human breast carcinomas.
Life Sci Volume: 84 Page(s): 766 - 771
05/22/2009 Authors: Ali S; Al-Sukhun S; El-Rayes BF; Sarkar FH; Heilbrun LK; Philip PA
A retrospective review of squamous cell carcinoma of the anal canal in HIV-positive and HIV-negative patients
Volume: 27
05/20/2009 Authors: Hammad N; Philip PA; Shields AF; Heilbrun LK; Venkatramanamoorthy R; El-Rayes BF
(18)F-Fluorodeoxyglucose positron emission tomography (FDG-PET) as a prognostic and predictive biomarker in metastatic colorectal cancer (mCRC).
J Clin Oncol Volume: 27 Page(s): e15037
05/20/2009 Authors: Philip PA; Gupta S; Heilbrun L; Smith D; El-Rayes B; Shields A
F-18-Fluorodeoxyglucose positron emission tomography (FDG-PET) as a prognostic and predictive biomarker in metastatic colorectal cancer (mCRC)
Volume: 27
05/20/2009 Authors: Philip PA; Gupta S; Heilbrun L; Smith D; El-Rayes B; Shields A
A phase II study of bevacizumab, docetaxel, and oxaliplatin in gastric and GEJ cancer
Volume: 27
05/20/2009 Authors: El-Rayes BF; Patel B; Zalupski M; Hammad N; Shields A; Heilbrun L; Venkatramanamoorthy R; Philip P
Exploitation of protein kinase C: a useful target for cancer therapy.
Cancer Treat Rev Volume: 35 Page(s): 1 - 8
02/01/2009 Authors: Ali AS; Ali S; El-Rayes BF; Philip PA; Sarkar FH
Ritonavir mediated protection of retinoblastoma-E2F-1 complex at G1 phase of cell cycle in pancreatic cancer cell lines
Volume: 207 Page(s): S97 - S97
09/01/2008 Authors: Batchu RB; Prasad M; Steffes C; Shammas M; El-Rayes BF; Weaver DW
Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer.
Mol Cancer Ther Volume: 7 Page(s): 1708 - 1719
06/01/2008 Authors: Ali S; Banerjee S; Ahmad A; El-Rayes BF; Philip PA; Sarkar FH
A phase II study of isoflavone, gemcitabine, and erlotinib in locally advanced (LA) or metastatic pancreatic cancer
JOURNAL OF CLINICAL ONCOLOGY Volume: 26
05/20/2008 Authors: Hammad N; Philip PA; Shields AF; Sarkar FH; Abruzzese JL; Kaseb AO; Javle MM; Varadhachary GR; Wolff RA; El-Rayes BF
A comparison of advanced pancreatic cancer patients treated on clinical trials with those from a SEER registry over an 18 year period
JOURNAL OF CLINICAL ONCOLOGY Volume: 26
05/20/2008 Authors: Jasti P; El-Rayes BF; Heilbrun LK; Philip PA; Zalupski MM; Shields AF; Venkatramanamoorthy R; Severson R
A phase II study of bevacizumab, docetaxel and oxaliplatin in gastric and gastroesophageal junction (GEJ) cancer
JOURNAL OF CLINICAL ONCOLOGY Volume: 26
05/20/2008 Authors: El-Rayes BF; Hammad N; Philip PA; Shields AF; Heilbrun LK
Protein kinase C: a target for therapy in pancreatic cancer.
Pancreas Volume: 36 Page(s): 346 - 352
05/01/2008 Authors: El-Rayes BF; Ali S; Philip PA; Sarkar FH
Ritonavir, a protease inhibitor, induces apoptosis in pancreatic cancer cells by inhibiting the AKT signaling pathway
GASTROENTEROLOGY Volume: 134 Page(s): A740 - A740
04/01/2008 Authors: Bryant CS; Kumar S; El-Rayes B; Qazi A; Steffes CP; Prasad M; Weaver DW; Shammas MA; Batchu RB
Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.
Cancer Chemother Pharmacol Volume: 61 Page(s): 283 - 289
02/01/2008 Authors: El-Rayes BF; Zalupski MM; Manza SG; Rusin B; Ferris AM; Vaishampayan U; Heilbrun LK; Venkatramanamoorthy R; Shields AF; Philip PA
Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site.
Cancer Volume: 110 Page(s): 770 - 775
08/15/2007 Authors: Schneider BJ; El-Rayes B; Muler JH; Philip PA; Kalemkerian GP; Griffith KA; Zalupski MM
A phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer.
Am J Clin Oncol Volume: 30 Page(s): 340 - 345
08/01/2007 Authors: Desai SP; El-Rayes BF; Ben-Josef E; Greenson JK; Knol JA; Huang EH; Griffith KA; Philip PA; McGinn CJ; Zalupski MM
CA 19-9 as a predictor of response and survival in patients with pancreatic cancer treated with gemcitabine and cisplatin based chemotherapy
Volume: 25
06/20/2007 Authors: Heilbrun LK; Khanna A; Venkatramanamoorthy R; Shields AF; Philip PA; Zalupski MM; El-Rayes BF
A phase I study of gemcitabine and uracil-ftorfar (UFT)/leucovorin.
Am J Clin Oncol Volume: 30 Page(s): 101 - 105
04/01/2007 Authors: El-Rayes BF; Zalupski M; Shields AF; Manza SG; LoRusso P; Philip PA
Phase I study of bryostatin 1 and gemcitabine.
Clin Cancer Res Volume: 12 Page(s): 7059 - 7062
12/01/2006 Authors: El-Rayes BF; Gadgeel S; Shields AF; Manza S; Lorusso P; Philip PA
Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB.
Cancer Res Volume: 66 Page(s): 10553 - 10559
11/01/2006 Authors: El-Rayes BF; Ali S; Ali IF; Philip PA; Abbruzzese J; Sarkar FH
A phase I study of flavopiridol and docetaxel.
Invest New Drugs Volume: 24 Page(s): 305 - 310
07/01/2006 Authors: El-Rayes BF; Gadgeel S; Parchment R; Lorusso P; Philip PA
The role of venography in the evaluation of malfunctioning central venous access ports (CVAPs).
J Clin Oncol Volume: 24 Page(s): 18535
06/20/2006 Authors: Atallah E; Salomon M; Schiffer CA; El-Rayes B
A dose attenuated schedule of irinotecan and capecitabine in combination with celecoxib in advanced colorectal cancer.
Volume: 24 Page(s): 166S - 166S
06/20/2006 Authors: El-Rayes BF; Shields AF; Vaishampayan U; Heilbrun LK; Zalupski MM; Philip PA
A retrospective review of anal squamous cell carcinoma in HIV positive and HIV negative patients.
Volume: 24 Page(s): 215S - 215S
06/20/2006 Authors: Grandhi J; Philip PA; Washington T; Shields AF; Vaishampayan U; Heilburn LK; Venkatramanamoorthy R; El-Rayes BF
Phase II study of celecoxib, irinotecan, and capecitabine in patients with advanced colorectal cancer
Volume: 17 Page(s): 70 - 70
01/01/2006 Authors: El-Rayes B; Shields A; Zalupski M; Bekaii-Saab T; Heilbrun L; Vaishampayan U; Manza S
Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy.
Mol Cancer Ther Volume: 4 Page(s): 1943 - 1951
12/01/2005 Authors: Ali S; El-Rayes BF; Sarkar FH; Philip PA
A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer.
Invest New Drugs Volume: 23 Page(s): 583 - 590
12/01/2005 Authors: El-Rayes BF; Zalupski MM; Shields AF; Ferris AM; Vaishampayan U; Heilbrun LK; Venkatramanamoorthy R; Adsay V; Philip PA
CA 19-9 as a predictor of response and survival in patients with pancreatic cancer treated with gemcitabine and cisplatin based chemotherapy.
Volume: 23 Page(s): 355S - 355S
06/01/2005 Authors: Patel B; Heilburn L; Khanna A; Venkatramanamoorthy R; Shields A; Philip P; Zalupski M; El-Rayes B
A phase II trial of celecoxib, irinotecan, and capecitabine in metastatic colorectal cancer.
Volume: 23 Page(s): 290S - 290S
06/01/2005 Authors: El-Rayes BF; Zalupski MM; Shields AF; Heilbrun LK; Bekaii-Saab T; Vaishampayan U; Philip PA
A phase II trial of carboplatin, gemcitabine and capecitabine in patients with carcinoma of unknown primary site (CUP).
Volume: 23 Page(s): 330S - 330S
06/01/2005 Authors: Schneider BJ; Muler J; Philip P; Kalemkerian G; El-Rayes B; Griffith K; Zalupski M
A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary.
Am J Clin Oncol Volume: 28 Page(s): 152 - 156
04/01/2005 Authors: El-Rayes BF; Shields AF; Zalupski M; Heilbrun LK; Jain V; Terry D; Ferris AM; Philip PA
Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer cells.
Breast Cancer Res Treat Volume: 90 Page(s): 25 - 31
03/01/2005 Authors: Ali S; El-Rayes BF; Aranha O; Sarkar FH; Philip PA
Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors.
Invest New Drugs Volume: 23 Page(s): 57 - 62
01/01/2005 Authors: El-Rayes BF; Ibrahim D; Shields AF; LoRusso PM; Zalupski MM; Philip PA
Cellular DNA content parameters as prognostic indicators in human astrocytomas.
J Neurooncol Volume: 71 Page(s): 85 - 89
01/01/2005 Authors: El-Rayes BF; Norton CS; Sakr W; Maciorowski Z; Smith D; Pietraszkiewicz H; Del Mar Alonso M; Ensley JF
Pseudoaneuploid subpopulations detected in normal upper aerodigestive tract mucosa consistent with physiological apoptosis in normally differentiating squamous mucosa.
Otolaryngol Head Neck Surg Volume: 131 Page(s): 633 - 638
11/01/2004 Authors: El-Rayes BF; Korkmaz H; Maciorowski Z; Sakr W; Jacobs JR; Ensley JF
Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines.
Mol Cancer Ther Volume: 3 Page(s): 1421 - 1426
11/01/2004 Authors: El-Rayes BF; Ali S; Sarkar FH; Philip PA
Targeting the epidermal growth factor receptor.
Br J Cancer Volume: 91 Page(s): 418 - 424
08/02/2004 Authors: El-Rayes BF; LoRusso PM
Phase II study of capecitabine, irinotecan, and celecoxib in advanced colorectal cancer.
Volume: 22 Page(s): 310S - 310S
07/15/2004 Authors: El-Rayes BF; Shields AF; Vaishampayan U; Heilbrun L; Bekaii-Saab T; Zalupski MM; Philip PA
A phase II study of gemcitabine by fixed-dose rate infusion, cisplatin, and celecoxib in metastatic pancreatic cancer.
Volume: 22 Page(s): 343S - 343S
07/15/2004 Authors: Kobrossy B; El-Rayes BF; Shields AF; Vaishampayan U; Heilbrun L; Zalupski MM; Philip PA
Cytochrome p450 and glutathione transferase expression in squamous cell cancer.
Clin Cancer Res Volume: 10 Page(s): 4412 - 4416
07/01/2004 Authors: Ali S; El-Rayes BF; Heilbrun LK; Sarkar FH; Ensley JF; Kucuk O; Philip PA
A phase II study of carboplatin and paclitaxel in esophageal cancer.
Ann Oncol Volume: 15 Page(s): 960 - 965
06/01/2004 Authors: El-Rayes BF; Shields A; Zalupski M; Heilbrun LK; Jain V; Terry D; Ferris A; Philip PA
Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.
Int J Radiat Oncol Biol Phys Volume: 59 Page(s): 454 - 459
06/01/2004 Authors: Ben-Josef E; Shields AF; Vaishampayan U; Vaitkevicius V; El-Rayes BF; McDermott P; Burmeister J; Bossenberger T; Philip PA
Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line.
Pancreas Volume: 28 Page(s): e90 - e95
05/01/2004 Authors: Li Y; Ellis K-L; Ali S; El-Rayes BF; Nedeljkovic-Kurepa A; Kucuk O; Philip PA; Sarkar FH
Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer.
J Clin Oncol Volume: 21 Page(s): 2920 - 2925
08/01/2003 Authors: El-Rayes BF; Zalupski MM; Shields AF; Vaishampayan U; Heilbrun LK; Jain V; Adsay V; Day J; Philip PA
Cytochrome p450 and glutathione transferase expression in human breast cancer.
Clin Cancer Res Volume: 9 Page(s): 1705 - 1709
05/01/2003 Authors: El-Rayes BF; Ali S; Heilbrun LK; Lababidi S; Bouwman D; Visscher D; Philip PA
Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer.
Urology Volume: 61 Page(s): 774 - 780
04/01/2003 Authors: Hussain M; Smith DC; El-Rayes BF; Du W; Vaishampayan U; Fontana J; Sakr W; Wood D
Hormone-refractory prostate cancer responding to capecitabine
UROLOGY Volume: 61
02/01/2003 Authors: El-Rayes BF; Black CA; Ensley JF
Unusual case of antiphospholipid antibody syndrome presenting with extensive cutaneous infarcts in a patient on long-term procainamide therapy.
Am J Hematol Volume: 72 Page(s): 154
02/01/2003 Authors: El-Rayes BF; Edelstein M
Comparison of DNA content parameters in paired, fresh tissue pretreatment biopsies and surgical resections from squamous cell carcinoma of the head and neck.
Otolaryngol Head Neck Surg Volume: 128 Page(s): 169 - 177
02/01/2003 Authors: El-Rayes BF; Maciorowski Z; Pietraszkiewicz H; Ensley JF
Hormone-refractory prostate cancer responding to capecitabine.
Urology Volume: 61 Page(s): 462
02/01/2003 Authors: El-Rayes BF; Black CA; Ensley JF
Developments in the systemic therapy of pancreatic cancer.
Cancer Invest Volume: 21 Page(s): 73 - 86
01/01/2003 Authors: el-Rayes BF; Shields AF; Vaitkevicius V; Philip PA
Vascular access thrombosis and hypercoagulable states in patients with end stage renal disease on hemodialsis.
Volume: 100 Page(s): 270A - 270A
11/16/2002 Authors: El-Rayes BF; Amm JMA; Sondheimer JH; Andersen JC
Breast cancer in women with human immunodeficiency virus infection: implications for diagnosis and therapy.
Breast Cancer Res Treat Volume: 76 Page(s): 111 - 116
11/01/2002 Authors: El-Rayes BF; Berenji K; Schuman P; Philip PA
Broad array of coagulation defects in patients with membranous nephropathy and minimal change disease.
Volume: 13 Page(s): 676A - 676A
09/01/2002 Authors: Amm JMA; El-Rayes BF; Andersen JC; Rossi NF
Vascular access thrombosis and hypercoagulable states.
Volume: 13 Page(s): 713A - 713A
09/01/2002 Authors: Amm JMA; El-Rayes BF; Andersen JC; Sondheimer JH
Systemic therapy for advanced pancreatic cancer.
Expert Rev Anticancer Ther Volume: 2 Page(s): 426 - 436
08/01/2002 Authors: El-Rayes BF; Philip PA
Ciprofloxacin inhibits cell growth and synergises the effect of etoposide in hormone resistant prostate cancer cells.
Int J Oncol Volume: 21 Page(s): 207 - 211
07/01/2002 Authors: El-Rayes BF; Grignon R; Aslam N; Aranha O; Sarkar FH
Hormonal therapy for prostate cancer: past, present and future.
Expert Rev Anticancer Ther Volume: 2 Page(s): 37 - 47
02/01/2002 Authors: el-Rayes BF; Hussain MH
Pancreatic cancer: the evolving role of systemic therapy.
Expert Opin Pharmacother Volume: 2 Page(s): 1939 - 1947
12/01/2001 Authors: Adsay NV; El-Rayes BF; Philip PA
Long term comparison of event free and overall survival in patients with non-Hodgkin's lymphoma (NHL) treated with autologous or allogeneic marrow/stem cell transplantation on a single protocol over a 12 year period.
Volume: 98 Page(s): 680A - 680A
11/16/2001 Authors: El-rayes BF; Abella E; Dansey R; Klein JL; Hamm C; Karanes C; Baynes RD
Traumatic war neurosis: Egyptian experience.
J R Army Med Corps Volume: 128 Page(s): 67 - 71
06/01/1982 Authors: El Sudany El Rayes BM

Directory section navigation

Profile

Bassel El-Rayes MD

Academic Appointment

Education

Degrees

Research

Focus

Publications